302 results on '"Goebel, FD"'
Search Results
2. Severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir: case report
- Author
-
Jülg, Boris, Bogner, JR, and Goebel, FD
- Published
- 2006
- Full Text
- View/download PDF
3. Klinische Variabilität des autosomal-dominanten Diabetes des Jugendalters (MODY)*
- Author
-
Goebel Fd and Füessl Hs
- Subjects
Coma ,Pediatrics ,medicine.medical_specialty ,business.industry ,Insulin ,medicine.medical_treatment ,Metabolic disorder ,General Medicine ,Disease ,medicine.disease ,Nephropathy ,Diabetes mellitus ,Metabolic control analysis ,medicine ,Juvenile ,medicine.symptom ,business - Abstract
Occurrence prior to the age of 25 years, dominant inheritance, metabolic control without insulin for more than two years and mild course without late complications are considered characteristic of maturity-onset diabetes of young people (MODY). Diabetes or glucose tolerance disturbance was observed in 30 members of a family in five successive generations. The course of the disease within the family was variable: even after disease for several decades no diabetes-specific late complications were seen in 20 diabetics, six, in contrast, had serious complications such as proliferative retinopathy, nephropathy and coma. The different clinical course is expression of the considerable variability of this genetically uniform metabolic disorder. Our observations demonstrate that vascular complications in MODY are less frequent than in type II diabetes, however are not excluded. Thus, also MODY diabetics require life-long careful metabolic surveillance.
- Published
- 2008
- Full Text
- View/download PDF
4. Prävention bei HIV-Infizierten
- Author
-
Goebel Fd
- Subjects
General Medicine - Published
- 2008
- Full Text
- View/download PDF
5. What�s New in the Treatment of Difficult Infectious Diseases?
- Author
-
Goebel Fd
- Subjects
Text mining ,business.industry ,Medicine ,business ,Data science - Published
- 2015
- Full Text
- View/download PDF
6. Optimaler Beginn der antiretroviralen Therapie bei HIV-positiven Patienten
- Author
-
Goebel Fd and Nitschmann S
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Proportional hazards model ,Disease progression ,Treatment outcome ,Human immunodeficiency virus (HIV) ,medicine.disease_cause ,Antiretroviral therapy ,Text mining ,Meta-analysis ,Internal medicine ,Internal Medicine ,medicine ,business ,Cohort study - Published
- 2010
- Full Text
- View/download PDF
7. Divertikulose des Duodenums
- Author
-
Wuttge R, Kellner H, Westermeier K, and Goebel Fd
- Subjects
Dietary fibres ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Mesogastric region ,General Medicine ,medicine.disease ,Surgery ,Diverticulosis ,Endoscopy ,Conservative treatment ,Regimen ,medicine.anatomical_structure ,Duodenum ,medicine ,Vomiting ,medicine.symptom ,business - Abstract
A 62-year-old woman was admitted to hospital because of extremely severe colicky pain in the mesogastric region and vomiting. Six years earlier two duodenal diverticles had been found to be responsible for similar symptoms. Endoscopy and X-ray examination now revealed four extensive duodenal diverticles, the largest of which had an extension of 8 X 7 cm. There were no diverticular complications. The patient became free from complaints by conservative treatment, at first with "zero" diet, then with a regimen rich in dietary fibres and frequent small meals. She remained symptom-free during a follow-up period of six months so far.
- Published
- 2008
- Full Text
- View/download PDF
8. Endoscopic Ultrasound in the Diagnosis and Staging of Gastrointestinal Kaposi's Sarcoma
- Author
-
H. Liess, W. G. Zoller, J. R. Bogner, F. Powitz, and Goebel Fd
- Subjects
Adult ,Male ,Endoscopic ultrasound ,medicine.medical_specialty ,medicine.medical_treatment ,Gastroenterology ,Lesion ,Clinical Trials, Phase II as Topic ,Internal medicine ,Immunopathology ,medicine ,Humans ,Prospective Studies ,Sarcoma, Kaposi ,Kaposi's sarcoma ,Gastrointestinal Neoplasms ,Neoplasm Staging ,Ultrasonography ,Chemotherapy ,medicine.diagnostic_test ,business.industry ,Endoscopy ,Middle Aged ,medicine.disease ,digestive system diseases ,Clinical Trials, Phase III as Topic ,Doxorubicin ,Sarcoma ,medicine.symptom ,Complication ,business - Abstract
Background and Study Aims: Endoscopic ultrasonography (EUS) has been evaluated for diagnosing and staging of a variety of gastrointestinal tumors, but there are no data on EUS in Kaposi's sarcoma (KS). The aim of the present study was to evaluate the role of EUS in addition to endoscopy in the diagnosis and staging of patients with established or suspected upper gastrointestinal KS. Patients and Methods: 22 male acquired immune deficiency syndrome (AIDS) patients were prospectively studied, three of them before and after chemotherapy with liposomal doxorubicin. The features of gastrointestinal KS were recorded, and EUS was assessed for diagnosis in endoscopically negative or inconclusive cases, and for staging in endoscopically visible KS lesions. ResuLts: The typical EUS feature of KS was a hypoechoic and nonhomogeneous lesion leading predominantly to mucosal and submucosal thickening, whereas a few lesions presented only with submucosal involvement. EUS detected suspicious lesions in two patients with negative endoscopy, which turned out to be KS on follow-up. Restaging after chemotherapy in three patients showed regression of lesions both on endoscopy and EUS. Conclusions: EUS may contribute to better detection of early KS lesions and a more reliable delineation of the extent of gastrointestinal KS, which is valuable for assessing the effect of various forms of therapy
- Published
- 1995
- Full Text
- View/download PDF
9. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
- Author
-
Antiretroviral Therapy Cohort Collaboration, Mugavero, Mj, May, M, Harris, R, Saag, Ms, Costagliola, D, Egger, M, Phillips, A, Günthard, Hf, Dabis, F, Hogg, R, de Wolf, F, Fatkenheuer, G, Gill, Mj, Justice, A, D'Arminio Monforte, A, Lampe, F, Miró, Jm, Staszewski, S, Collaborators: Casabona J, Sterne J. A., Geneviè, C, del Amo, J, Fätkenheuer, G, Gill, J, Guest, J, Kitahata, M, Ledergerber, B, Mocroft, A, Reiss, P, Saag, M, Sterne, J, Sterne, Ja, Abgrall, S, Barin, F, Bentata, M, Billaud, E, Boué, F, Burty, C, Cabié, A, Cotte, L, De Truchis, P, Duval, X, Duvivier, C, Enel, P, Fredouille Heripret, L, Gasnault, J, Gaud, C, Gilquin, J, Grabar, S, Katlama, C, Khuong, Ma, Lang, Jm, Lascaux, As, Launay, O, Mahamat, A, Mary Krause, M, Matheron, S, Meynard, Jl, Pavie, J, Pialoux, G, Pilorgé, F, Poizot Martin, I, Pradier, C, Reynes, J, Rouveix, E, Simon, A, Tattevin, P, Tissot Dupon, H, Viard, Jp, Viget, N, Pariente Khayat, A, Salomon, V, Jacquemet, N, Rivet, A, Abgral, S, Guiguet, M, Kousignian, I, Lanoy, E, Lièvre, L, Potard, V, Selinger Leneman, H, Bouvet, E, Crickx, B, Ecobichon, Jl, Leport, C, Picard Dahan, C, Yeni, P, Tisne Dessus, D, Weiss, L, Salmon, D, Sicard, D, Auperin, I, Roudière, L, Fior, R, Delfraissy, Jf, Goujard, C, Jung, C, Lesprit, P, Desplanque, N, Meyohas, Mc, Picard, O, Cadranel, J, Mayaud, C, Bricaire, F, Herson, S, Clauvel, Jp, Decazes, Jm, Gerard, L, Molina, Jm, Diemer, M, Sellier, P, Berthé, H, Dupont, C, Chandemerle, C, Mortier, E, de Truchis, P, Honoré, P, Jeantils, V, Tassi, S, Mechali, D, Taverne, B, Gourdon, F, Laurichesse, H, Fresard, A, Lucht, F, Eglinger, P, Faller, Jp, Bazin, C, Verdon, R, Boibieux, A, Peyramond, D, Livroze, Jm, Touraine, Jl, Trepo, C, Ravaux, I, Tissot Dupont, H, Delmont, Jp, Moreau, J, Gastaut, Ja, Retornaz, F, Soubeyrand, J, Allegre, T, Blanc, Pa, Galinier, A, Ruiz, Jm, Lepeu, G, Granet Brunello, P, Esterni, Jp, Pelissier, L, Cohen Valensi, R, Nezri, M, Chadapaud, S, Laffeuillade, A, Laffeuillade, J, May, T, Rabaud, C, Raffi, F, Pugliese, P, Arvieux, C, Michelet, C, Borsa Lebas, F, Caron, F, Fraisse, P, Rey, D, Arlet Suau, E, Cuzin, L, Massip, P, Thiercelin Legrand MF, Yasdanpanah, Y, Pradinaud, R, Sobesky, M, Contant, M, Montroni, M, Scalise, G, Braschi, Mc, Riva, A, Tirelli, U, Cinelli, R, Pastore, G, Ladisa, N, Suter, F, Arici, C, Chiodo, F, Colangeli, V, Fiorini, C, Carosi, Giampiero, Cristini, G, Torti, Carlo, Minardi, C, Bertelli, D, Quirino, T, Manconi, Pe, Piano, P, Cosco, L, Scerbo, A, Vecchiet, J, D'Alessandro, M, Santoro, D, Pusterla, L, Carnevale, G, Zoncada, A, Viganò, P, Mena, M, Ghinelli, F, Sighinolfi, L, Leoncini, F, Mazzotta, F, Pozzi, M, Lo Caputo, S, Angarano, G, Grisorio, B, Saracino, A, Ferrara, S, Grima, P, Grima, F, Pagano, G, Cassola, G, Alessandrini, A, Piscopo, R, Toti, M, Trezzi, M, Soscia, F, Tacconi, L, Orani, A, Perini, P, Scasso, A, Vincenti, A, Chiodera, F, Castelli, P, Scalzini, A, Palvarini, L, Moroni, M, Lazzarin, A, Rizzardini, G, d'Arminio Monforte, A, Galli, A, Merli, S, Pastecchia, C, Moioli, Mc, Esposito, R, Mussini, C, Abresci, N, Chirianni, A, Izzo, Cm, Piazza, M, De Marco, M, Viglietti, R, Manzillo, E, Nappa, S, Colomba, A, Abbadessa, V, Prestileo, T, Mancuso, S, Ferrari, C, Pizzaferri, P, Filice, G, Minoli, L, Bruno, R, Novati, S, Baldelli, F, Tinca, M, Petrelli, E, Cioppi, A, Cioppi, F, Ruggieri, A, Menichetti, F, Martinelli, C, De Stefano, C, La Gala, A, Ballardini, G, Rizzo, E, Magnani, G, Ursitti, Ma, Arlotti, M, Ortolani, P, Cauda, R, Dianzani, F, Ippolito, G, Antinori, A, Antonucci, G, Ciardi, M, Narciso, P, Petrosillo, N, Vullo, V, De Luca, A, Zaccarelli, M, Acinapura, R, De Longis, P, Brandi, A, Trotta, Mp, Noto, P, Lichtne, M, Capobianch, Mr, Carletti, F, Girardi, E, Pezzotti, P, Rezza, G, Mura, Ms, Mannazzu, M, Caramello, P, Di Perri, G, Sciandra, M, Orofino, Gc, Grossi, Pa, Basilico, C, Poggio, A, Bottari, G, Raise, E, Ebo, F, Pellizzer, G, Buonfrate, D, Resta, F, Loso, K, Cozzi Lepri, A, Battegay, M, Bernasconi, E, Böni, J, Bucher, Hc, Bürgisser, P, Calmy, A, Cattacin, S, Cavassini, M, Dubs, R, Elzi, L, Fischer, M, Flepp, M, Fontana, A, Francioli, P, Furrer, H, Fux, C, Gorgievski, M, Günthard, H, Hirsch, H, Hirschel, B, Hösli, I, Kahlert, Ch, Kaiser, L, Karrer, U, Kind, C, Klimkait, T, Martinetti, G, Martinez, B, Martinez, N, Nadal, D, Opravil, M, Paccaud, F, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schmid, P, Schultze, D, Schüpbach, J, Speck, R, Taffé, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Yerly, S, Gras, La, van Sighem AI, Smit, C, Prins, Jm, Branger, J, Eeftinck Schattenkerk JK, Gisolf, J, Godfried, Mh, Lange, Jm, Lettinga, Kd, van der Meer JT, Nellen, Fj, van der Poll, T, Ruys, Ta, Steingrover, R, Vermeulen, Jn, Vrouenraets, Sm, van Vugt, M, Wit, Fw, Kuijpers, Tw, Pajkrt, D, Scherpbier, Hj, van Eeden, A, Brinkman, K, van den Berk GE, Blok, Wl, Frissen, Ph, Roos, Jc, Schouten, We, Mulder, Jw, van Gorp EC, Wagenaar, J, Veenstra, J, Danner, Sa, Van Agtmael MA, Claessen, Fa, Perenboom, Rm, Rijkeboer, A, van Vonderen MG, Richter, C, van der Berg, J, Vriesendorp, R, Jeurissen, Fj, Kauffmann, Rh, Pogány, K, Bravenboer, B, Sprenger, Hg, van Assen, S, van Leeuwen JT, Doedens, R, Scholvinck, Eh, ten Kate RW, Soetekouw, R, van Houte, D, Polée, Mb, Kroon, Fp, van den Broek PJ, van Dissel JT, Schippers, Ef, Schreij, G, van der Geest, S, Lowe, S, Verbon, A, Koopmans, Pp, Van Crevel, R, de Groot, R, Keuter, M, Post, F, van der Ven AJ, Warris, A, van der Ende ME, Gyssens, Ic, van der Feltz, M, Nouwen, Jl, Rijnders, Bj, de Vries TE, Driessen, G, van der Flier, M, Hartwig, Ng, Juttman, Jr, van Kasteren ME, Van de Heul, C, Hoepelman, Im, Schneider, Mm, Bonten, Mj, Borleffs, Jc, Ellerbroek, Pm, Jaspers, Ca, Mudrikove, T, Schurink, Ca, Gisolf, Eh, Geelen, Sp, Wolfs, Tf, Faber, T, Tanis, Aa, Groeneveld, Ph, den Hollander JG, Duits, Aj, Winkel, K, Back, Nk, Bakker, Me, Berkhout, B, Jurriaans, S, Zaaijer, Hl, Cuijpers, T, Rietra, Pj, Roozendaal, Kj, Pauw, W, van Zanten AP, Smits, Ph, von Blomberg BM, Savelkoul, P, Pettersson, A, Swanink, Cm, Franck, Pf, Lampe, As, Jansen, Cl, Hendriks, R, Benne, Ca, Veenendaal, D, Storm, H, Weel, J, van Zeijl JH, Kroes, Ac, Claas, Hc, Bruggeman, Ca, Goossens, Vj, Galama, Jm, Melchers, Wj, Poort, Ya, Doornum, Gj, Niesters, Mg, Osterhaus, Ad, Schutten, M, Buiting, Ag, Swaans, Ca, Boucher, Ca, Schuurman, R, Boel, E, Jansz, Af, Veldkamp, A, Beijnen, Jh, Huitema, Ad, Burger, Dm, Hugen, Pw, van Kan HJ, Losso, M, Duran, A, Vetter, N, Karpov, I, Vassilenko, A, Clumeck, N, De Wit, S, Poll, B, Colebunders, R, Machala, L, Rozsypal, H, Sedlacek, D, Nielsen, J, Lundgren, J, Benfield, T, Kirk, O, Gerstoft, J, Katzenstein, T, Hansen, Ab, Skinhøj, P, Pedersen, C, Zilmer, K, Girard, Pm, Saint Marc, T, Vanhems, P, Dietrich, M, Manegold, C, van Lunzen, J, Stellbrink, Hj, Staszewsk, S, Bickel, M, Goebel, Fd, Rockstroh, J, Schmidt, R, Kosmidis, J, Gargalianos, P, Sambatakou, H, Perdios, J, Panos, G, Filandras, A, Karabatsaki, E, Banhegyi, D, Mulcahy, F, Yust, I, Turner, D, Burke, M, Pollack, S, Hassoun, G, Sthoeger, Z, Maayan, S, Chiesi, A, Borghi, R, Pristera, R, Mazzott, F, Gabbuti, A, Vullo, Lichtner, M, Montesarchio, E, Iacomi, F, Finazzi, R, Viksna, L, Chaplinskas, S, Hemmer, R, Staub, T, Bruun, J, Maeland, A, Ormaasen, V, Knysz, B, Gasiorowski, J, Horban, A, Prokopowicz, D, Wiercinska Drapalo, A, Boron Kaczmarska, A, Pynka, M, Beniowski, M, Mularska, E, Trocha, H, Antunes, F, Valadas, E, Mansinho, K, Matez, F, Duiculescu, D, Babes, V, Streinu Cercel, A, Vinogradova, E, Rakhmanova, A, Jevtovic, D, Mokrás, M, Staneková, D, González Lahoz, J, Sánchez Conde, M, García Benayas, T, Martin Carbonero, L, Soriano, V, Clotet, B, Jou, A, Conejero, J, Tural, C, Gatell, Jm, Blaxhult, A, Karlsson, A, Pehrson, P, Soravia Dunand, V, Kravchenko, E, Chentsova, N, Barton, S, Johnson, Am, Mercey, D, Johnson, Ma, Murphy, M, Weber, J, Scullard, G, Fisher, M, Brettle, R, Loveday, C, Gatell, J, Johnson, A, Vella, S, Gjørup, I, Friis Moeller, N, Bannister, W, Mollerup, D, Podlevkareva, D, Holkmann Olsen, C, Kjaer, J, Raffanti, S, Dieterch, D, Becker, S, Scarsella, A, Fusco, G, Most, B, Balu, R, Rana, R, Beckerman, R, Ising, T, Fusco, J, Irek, R, Johnson, B, Hirani, A, Dejesus, E, Pierone, G, Lackey, P, Irek, C, Burdick, J, Leon, S, Arch, J, Helm, Eb, Carlebach, A, Müller, A, Haberl, A, Nisius, G, Lennemann, T, Stephan, C, Mösch, M, Gute, P, Locher, L, Lutz, T, Klauke, S, Knecht, G, Khaykin, P, Doerr, Hw, Stürmer, M, Babacan, E, von Hentig, N, Beylot, J, Chêne, G, Dupon, M, Longy Boursier, M, Pellegrin, Jl, Ragnaud, Jm, Salamon, R, Thiébaut, R, Lewden, C, Lawson Ayayi, S, Mercié, P, Moreau, Jf, Morlat, P, Bernard, N, Lacoste, D, Malvy, D, Neau, D, Blaizeau, Mj, Decoin, M, Delveaux, S, Hannapier, C, Labarrère, S, Lavignolle Aurillac, V, Uwamaliya Nziyumvira, B, Palmer, G, Touchard, D, Balestre, E, Alioum, A, Jacqmin Gadda, H, Bonarek, M, Bonnet, F, Coadou, B, Gellie, P, Nouts, C, Bocquentin, F, Dutronc, H, Lafarie, S, Aslan, A, Pistonne, T, Thibaut, P, Vatan, R, Chambon, D, De La Taille, C, Cazorla, C, Ocho, A, Viallard, Jf, Caubet, O, Cipriano, C, Lazaro, E, Couzigou, P, Castera, L, Fleury, H, Lafon, Me, Masquelier, B, Pellegrin, I, Breilh, D, Blanco, P, Loste, P, Caunègre, L, Bonna, F, Farbos, S, Ferrand, M, Ceccaldi, J, Tchamgoué, S, De Witte, S, Buy, E, Akagi, L, Brandson, E, Druyts, E, Gataric, Kf, Harrigan, Pr, Harris, M, Hayden, A, Lima, V, Montaner, J, Moore, D, Wood, E, Yip, B, Zhang, W, Bhagani, S, Byrne, P, Carroll, A, Cuthbertson, Z, Dunleavy, A, Geretti, Am, Heelan, B, Johnson, M, Kinloch de Loes, S, Lipman, M, Madge, S, Marshall, N, Nair, D, Nebbia, G, Prinz, B, Swaden, L, Tyrer, M, Youle, M, Chaloner, C, Grabowska, H, Holloway, J, Puradiredja, J, Ransom, D, Tsintas, R, Bansi, L, Fox, Z, Harris, E, Hill, T, Lodwick, R, Reekie, J, Sabin, C, Smith, C, Amoah, E, Booth, C, Clewley, G, Garcia Diaz, A, Gregory, B, Labbett, W, Tahami, F, Thomas, M, Read, R, Krentz, H, Beckthold, B, Faetkenheuer, G, Casabona, J, Miró, Jl, Alquézar, A, Esteve, A, Podzamczer, D, Murillas, J, Romero, A, Agustí, C, Agüero, F, Ferrer, E, Riera, M, Segura, F, Segura, G, Force, L, Vilaró, J, Masabeu, A, García, I, Guadarrama, M, Montoliu, A, Ortega, N, Lazzari, E, Puchol, E, Sanchez, M, Blanco, Jl, Garcia Alcaide, F, Martinez, E, Mallolas, J, López Dieguez, M, García Goez JF, Sirera, G, Romeu, J, Negredo, E, Miranda, C, Capitan, Mc, Olmo, M, Barragan, P, Saumoy, M, Bolaof, F, Cabellos, C, Peña, C, Sala, M, Cervantes, M, Amengual, Mj, Navarro, M, Penelo, E, Barrufet, P, Willig, Jh, Raper, Jl, Allison, Jj, Kempf, Mc, Schumacher, Je, Wes, Ao, Lin, Hy, Pisu, M, Moneyham, L, Vance, D, Bachmann, L, Davies, Sl, Berner, E, Acosta, E, King, J, Savage, K, Nevin, C, Walton, Fb, Marler, Ml, Lawrence, S, Files Kennedy, B, Batey, Ds, Patil, Ma, Patil, U, Varshney, M, Gibson, E, Guzman, A, Rinehart, D, Justice, Ac, Fiellin, Da, Bryant, K, Rimland, D, Jones Taylor, C, Oursler, Ka, Titanji, R, Brown, S, Garrison, S, Rodriguez Barradas, M, Masozera, N, Goetz, M, Leaf, D, Simberkoff, M, Blumenthal, D, Leung, J, Butt, A, Hoffman, E, Gibert, C, Peck, R, Mattocks, K, Braithwaite, S, Brandt, C, Cook, R, Conigliaro, J, Crothers, K, Chang, J, Crystal, S, Day, N, Erdos, J, Freiberg, M, Kozal, M, Gaziano, M, Gerschenson, M, Good, B, Gordon, A, Goulet, J, Kraemer, K, Lim, J, Maisto, S, Miller, P, O'Connor, P, Papas, R, Rinaldo, C, Roberts, M, Samet, J, Cohen, D, Consorte, A, Gordon, K, Kidwai, F, Levin, F, Mcginnis, K, Rambo, M, Rogers, J, Skanderson, M, and Whitsett, F.
- Published
- 2008
10. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies
- Author
-
Monforte, A, Abrams, D, Pradier, C, Weber, R, Reiss, P, Bonnet, F, Kirk, O, Law, M, De Wit, S, Friis Møller, N, Phillips, An, Sabin, Ca, Lundgren, Jd, Collaborators: Collins S, Data Collection on Adverse Events of Anti HIV Drugs Study G. r. o. u. p., Loeliger, E, Tressler, R, Weller, I, Worm, Sw, Sjøl, A, Sawitz, A, Rickenbach, M, Pezzotti, P, Krum, E, Gras, L, Balestre, E, Sundström, A, Poll, B, Fontas, E, Torres, F, Petoumenos, K, Kjaer, J, de Wolf, F, Zaheri, S, Bronsveld, W, Hillebrand Haverkort ME, Prins, Jm, Bos, Jc, Schattenkerk, Jk, Geerlings, Se, Godfried, Mh, Lange, Jm, van Leth FC, Lowe, Sh, van der Meer JT, Nellen, Fj, Pogány, K, van der Poll, T, Ruys, Ta, Sankatsing, Sr, van Twillert, G, van der Valk, M, van Vonderen MG, Vrouenraets, Sm, van Vugt, M, Wit, Fw, van Eeden, A, ten Veen JH, van Dam PS, Roos, Jc, Brinkman, K, Frissen, Ph, Weigel, Hm, Mulder, Jw, van Gorp EC, Meenhorst, Pl, Mairuhu, At, Veenstra, J, Danner, Sa, Van Agtmael MA, Claessen, Fa, Perenboom, Rm, Rijkeboer, A, van Vonderen, M, Richter, C, van der Berg, J, van Leusen, R, Vriesendorp, R, Jeurissen, Fj, Kauffmann, Rh, Koger, El, Bravenboer, B, ten Napel CH, Kootstra, Gj, Sprenger, Hg, Miesen, Wm, Doedens, R, Scholvinck, Eh, ten Kate RW, van Houte DP, Polee, M, Kroon, Fp, van den Broek, van Dissel JT, Schippers, Ef, Schreij, G, van de Geest, S, Verbon, A, Koopmans, Pp, Keuter, M, Post, F, van der Ven AJ, van der Ende ME, Gyssens, Ic, van der Feltz, M, den Hollander JG, de Marie, S, Nouwen, Jl, Rijnders, Bj, de Vries TE, Juttmann, Jr, van de Heul, C, van Kasteren ME, St Elisabeth SM, Bonten, Mj, Borleffs, Jc, Ellerbroek, Pm, Hoepelman, Im, Jaspers, Ca, Schouten, I, Schurink, Ca, Blok, Wl, Tanis, Aa, Groeneveld, Ph, Salamon, R, Beylot, J, Dupon, M, Le Bras, M, Pellegrin, Jl, Ragnaud, Jm, Dabis, F, Chêne, G, Jacqmin Gadda, H, Thiébaut, R, Lawson Ayayi, S, Lavignolle, V, Blaizeau, Mj, Decoin, M, Formaggio, Am, Delveaux, S, Labarerre, S, Uwamaliya, B, Vimard, E, Merchadou, L, Palmer, G, Touchard, D, Dutoit, D, Pereira, F, Boulant, B, Morlat, P, Bernard, N, Bonarek, M, Coadou, B, Gelie, P, Jaubert, D, Nouts, C, Lacoste, D, Dutronc, H, Cipriano, G, Lafarie, S, Chossat, I, Lacut, Jy, Leng, B, Mercié, P, Viallard, Jf, Faure, I, Rispal, P, Cipriano, C, Tchamgoué, S, Djossou, F, Malvy, D, Pivetaud, Jp, Chambon, D, De La Taille, C, Galperine, T, Neau, D, Ochoa, A, Beylot, C, Doutre, Ms, Bezian, Jh, Moreau, Jf, Taupin, Jl, Conri, C, Constans, J, Couzigou, P, Castera, L, Fleury, H, Lafon, Me, Masquelier, B, Pellegrin, I, Trimoulet, P, Moreau, F, Mestre, C, Series, C, Taytard, A, Glenday, K, Anderson, J, Cortissos, P, Mijch, A, Watson, K, Roth, N, Nicolson, J, Bloch, M, Agrawal, S, Franic, T, Baker, D, Vale, R, Carr, A, Cooper, D, Lacey, M, Hesse, K, Chuah, J, Lester, D, Fankhauser, W, Mallal, S, Forsdyke, C, Bulgannawar, S, Calvo, G, Mateu, S, Domingo, P, Sambeat, Ma, Gatell, J, Del Cacho, E, Cadafalch, J, Fuster, M, Codina, C, Sirera, G, Vaqué, A, Clumeck, N, Gerard, M, Kabeya, K, Konopnicki, D, Libois, A, Payen, Mc, Van Laethem, Y, Neaton, J, Bartsch, G, El Sadr WM, Thompson, G, Wentworth, D, Luskin Hawk, R, Telzak, E, Abrams, Di, Cohn, D, Markowitz, N, Arduino, R, Mushatt, D, Friedland, G, Perez, G, Tedaldi, E, Fisher, E, Gordin, F, Crane, Rl, Sampson, J, Baxter, J, Olsen, Ch, Mocroft, A, Vetter, N, Karpov, I, Vassilenko, A, Colebunders, R, Machala, L, Rozsypal, H, Sedlacek, D, Nielsen, J, Benfield, T, Gerstoft, J, Katzenstein, T, Hansen, Ab, Skinhøj, P, Pedersen, C, Zilmer, K, Katlama, C, Viard, Jp, Girard, Pm, Saint Marc, T, Vanhems, P, Dietrich, M, Manegold, C, van Lunzen, J, Stellbrink, Hj, Staszewski, S, Bieckel, M, Goebel, Fd, Fätkenheuer, C, Rockstroh, J, Schmidt, Re, Kosmidis, J, Gargalianos, P, Sambatakou, H, Perdios, J, Panos, G, Filandras, A, Banhegyi, D, Mulcahy, F, Yust, I, Burke, M, Turner, D, Pollack, S, Hassoun, J, Sthoeger, Z, Maayan, S, Vella, S, Chiesi, A, Arici, C, Pristerá, R, Mazzotta, F, Gabbuti, A, Esposito, R, Bedini, A, Chirianni, A, Montesarchio, E, Vullo, V, Santopadre, P, Narciso, P, Antinori, A, Franci, P, Zaccarelli, M, Lazzarin, A, Castagna, A, Viksna, L, Chaplinskas, S, Hemmer, R, Staub, T, Bruun, J, Maeland, A, Ormaasen, V, Knysz, B, Gasiorowski, J, Horban, A, Prokopowicz, D, Wiercinska Drapalo, A, Boron Kaczmarska, A, Pynka, M, Beniowski, M, Mularska, E, Trocha, H, Antunes, F, Mansinho, K, Maltez, F, Duiculescu, D, Babes, V, Streinu Cercel, A, Vinogradova, E, Rakhmanova, A, Jevtovic, D, Mokrás, M, Staneková, D, González Lahoz, J, Sanchez Conde, M, García Benayas, T, Martin Carbonero, L, Soriano, V, Clotet, B, Jou, A, Conejero, J, Ruiz, L, Tural, C, Gatell, Jm, Miró, Jm, Zamora, L, Blaxhult, A, Karlsson, A, Pehrson, P, Ledergerber, B, Francioli, P, Telenti, A, Hirschel, B, Soravia Dunand, V, Furrer, H, Kravchenko, E, Chentsova, N, Fisher, M, Brettle, R, Barton, S, Johnson, Am, Mercey, D, Murphy, M, Johnson, Ma, Weber, J, Scullard, G, Morfeldt, L, Thulin, G, Akerlund, B, Koppel, K, Flamholc, L, Håkangård, C, Ammassari, A, Maggiolo, F, Balotta, C, Bonfanti, P, Capobianchi, M, Ceccherini Silberstein, F, Cozzi Lepri, A, De Luca, A, Gervasoni, C, Girardi, E, Lo Caputo, S, Murri, R, Mussini, C, Puoti, M, Torti, Carlo, Moroni, M, Carosi, Giampiero, Cauda, R, Chiodo, F, Di Perri, G, Galli, M, Iardino, R, Ippolito, G, Panebianco, R, Pastore, G, Perno, Cf, Montroni, M, Scalise, G, Costantini, A, Riva, A, Tirelli, U, Martellotta, F, Ladisa, N, Suter, F, Colangeli, V, Fiorini, C, Carosi, G, Cristini, G, Torti, C, Minardi, C, Bertelli, D, Quirino, T, Manconi, Pe, Piano, P, Pizzigallo, E, D'Alessandro, M, Carnevale, G, Zoncada, A, Ghinelli, F, Sighinolfi, L, Leoncini, F, Pozzi, M, Grisorio, B, Ferrara, S, Pagano, G, Cassola, G, Alessandrini, A, Piscopo, R, Soscia, F, Tacconi, L, Orani, A, Perini, P, Tommasi, D, Congedo, P, Chiodera, F, Castelli, P, Rizzardini, G, Caggese, L, Galli, A, Merli, S, Pastecchia, C, Moioli, Mc, Gori, A, Cagni, S, Abrescia, N, Izzo, Cm, De Marco, M, Viglietti, R, Manzillo, E, Ferrari, C, Pizzaferri, P, Filice, G, Bruno, R, Magnani, G, Ursitti, Ma, Arlotti, M, Ortolani, P, Andreoni, M, Antonucci, G, Tozzi, V, Acinapura, R, De Longis, P, Trotta, Mp, Lichtner, M, Carletti, F, Mura, Mc, Mannazzu, M, Caramello, P, Orofino, Gc, Sciandra, M, Raise, E, Ebo, F, Pellizzer, G, Buonfrate, D, Caissotti, C, Dellamonica, P, Bentz, L, Bernard, E, De Salvador Guillouet, F, Durant, J, Mondain Miton, V, Perbost, I, Prouvost Keller, B, Pugliese, P, Rahelinirina, V, Roger, Pm, Vandenbos, F, Battegay, M, Bernasconi, E, Böni, J, Bucher, H, Bürgisser, P, Cattacin, S, Cavassini, M, Dubs, R, Egger, M, Elzi, L, Erb, P, Fischer, M, Flepp, M, Fontana, A, Furrer, Hj, Gorgievski, M, Günthard, H, Kaiser, L, Kind, C, Klimkait, T, Lauper, U, Opravil, M, Paccaud, F, Pantaleo, G, Perrin, L, Piffaretti, Jc, Schmid, Cr, Schüpbach, J, Speck, R, Trkola, A, Vernazza, P, and Yerly, S.
- Published
- 2008
11. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction
- Author
-
Data Collection on Adverse Events of Anti HIV Drugs Study Group, Sabin, Ca, d'Arminio Monforte, A, Friis Moller, N, Weber, R, El Sadr WM, Reiss, P, Kirk, O, Mercie, P, Law, Mg, De Wit, S, Pradier, C, Phillips, An, Collaborators: Lundgren JD, Lundgren J. D., Collins, S, Loeliger, E, Tressler, R, Weller, I, Friis Møller, N, Worm, Sw, Sjøl, A, Sawitz, A, Rickenbach, M, Pezzotti, P, Krum, E, Gras, L, Balestre, E, Sundström, A, Poll, B, Fontas, E, Torres, F, Petoumenos, K, Kjaer, J, de Wolf, F, Zaheri, S, Bronsveld, W, Hillebrand Haverkort ME, Prins, Jm, Bos, Jc, Eeftinck Schattenkerk JK, Geerlings, Se, Godfried, Mh, Lange, Jm, van Leth FC, Lowe, Sh, van der Meer JT, Nellen, Fj, Pogány, K, van der Poll, T, Ruys, Ta, Sankatsing, S, Steingrover, R, van Twillert, G, van der Valk, M, van Vonderen MG, Vrouenraets, Sm, van Vugt, M, Wit, Fw, van Eeden, A, ten Veen JH, van Dam PS, Roos, Jc, Brinkman, K, Frissen, Ph, Weigel, Hm, Mulder, Jw, van Gorp EC, Meenhorst, Pl, Mairuhu, At, Veenstra, J, Danner, Sa, Van Agtmael MA, Claessen, Fa, Perenboom, Rm, Rijkeboer, A, van Vonderen, M, Richter, C, van der Berg, J, van Leusen, R, Vriesendorp, R, Jeurissen, Fj, Kauffmann, Rh, Koger, El, Bravenboer, B, ten Napel CH, Kootstra, Gj, Sprenger, Hg, Miesen, Wm, Doedens, R, Scholvinck, Eh, ten Kate RW, van Houte DP, Polee, M, Kroon, Fp, van den Broek PJ, van Dissel JT, Schippers, Ej, Schreij, G, van de Geest PJ, Verbon, A, Koopmans, Pp, Keuter, M, Post, F, van der Ven AJ, van der Ende ME, Gyssens, Ic, van der Feltz, M, den Hollander JG, de Marie, S, Nouwen, Jl, Rijnders, Bj, de Vries TE, Juttmann, Jr, van de Heul, C, van Kasteren ME, Elisabeth, S, Schneider, Mm, Bonten, Mj, Borleffs, Jc, Ellerbroek, Pm, Hoepelman, Im, Jaspers, Ca, Schouten, I, Schurink, Ca, Blok, Wl, Tanis, Aa, Groeneveld, Ph, Salamon, R, Beylot, J, Dupon, M, Le Bras, M, Pellegrin, Jl, Ragnaud, Jm, Dabis, F, Chêne, G, Jacqmin Gadda, H, Thiébaut, R, Lawson Ayayi, S, Lavignolle, V, Blaizeau, Mj, Decoin, M, Formaggio, Am, Delveaux, S, Labarerre, S, Uwamaliya, B, Vimard, E, Merchadou, L, Palmer, G, Touchard, D, Dutoit, D, Pereira, F, Boulant, B, Morlat, P, Bernard, N, Bonarek, M, Bonnet, F, Coadou, B, Gelie, P, Jaubert, D, Nouts, C, Lacoste, D, Dutronc, H, Cipriano, G, Lafarie, S, Chossat, I, Lacut, Jy, Leng, B, Mercié, P, Viallard, Jf, Faure, I, Rispal, P, Cipriano, C, Tchamgoué, S, Djossou, F, Malvy, D, Pivetaud, Jp, Chambon, D, De La Taille, C, Galperine, T, Neau, D, Ochoa, A, Beylot, C, Doutre, Ms, Bezian, Jh, Moreau, Jf, Taupin, Jl, Conri, C, Constans, J, Couzigou, P, Castera, L, Fleury, H, Lafon, Me, Masquelier, B, Pellegrin, I, Trimoulet, P, Moreau, F, Mestre, C, Series, C, Taytard, A, Law, M, Anderson, J, Lowe, K, Mijch, A, Watson, K, Roth, N, Wood, H, Bloch, M, Gowers, A, Baker, D, Mcfarlane, R, Carr, A, Cooper, D, Chuah, J, Fankhauser, W, Mallal, S, Skett, J, Calvo, G, Mateu, S, Domingo, P, Sambeat, Ma, Gatell, J, Del Cacho, E, Cadafalch, J, Fuster, M, Codina, C, Sirera, G, Vaqué, A, Clumeck, N, Gerard, M, Kabeya, K, Konopnicki, D, Libois, A, Payen, Mc, Van Laethem, Y, Neaton, J, Thompson, G, Wentworth, D, Luskin Hawk, R, Telzak, E, Abrams, Di, Cohn, D, Markowitz, M, Crane, Lr, Arduino, R, Mushatt, D, Friedland, G, Perez, G, Tedaldi, E, Fisher, E, Gordin, F, Sampson, J, Baxter, J, Olsen, Ch, Mocroft, A, Lundgren, Jd, Vetter, N, Karpov, I, Vassilenko, A, Colebunders, R, Machala, L, Rozsypal, H, Sedlacek, D, Nielsen, J, Benfield, T, Gerstoft, J, Katzenstein, T, Hansen, Ab, Skinhøj, P, Pedersen, C, Zilmer, K, Katlama, C, Viard, Jp, Girard, Pm, Saint Marc, T, Vanhems, P, Dabis, C, Dietrich, M, Manegold, C, van Lunzen, J, Stellbrink, Hj, Staszewski, S, Bieckel, M, Goebel, Fd, Fätkenheuer, G, Rockstroh, J, Schmidt, Re, Kosmidis, J, Gargalianos, P, Sambatakou, H, Perdios, J, Panos, G, Filandras, A, Banhegyi, D, Mulcahy, F, Yust, I, Burke, M, Turner, D, Pollack, S, Hassoun, J, Sthoeger, Z, Maayan, S, Vella, S, Chiesi, A, Arici, C, Pristerá, R, Mazzotta, F, Gabbuti, A, Esposito, R, Bedini, A, Chirianni, A, Montesarchio, E, Vullo, V, Santopadre, P, Narciso, P, Antinori, A, Franci, P, Zaccarelli, M, Lazzarin, A, Castagna, A, D'Arminio Monforte, A, Viksna, L, Chaplinskas, S, Hemmer, R, Staub, T, Bruun, J, Maeland, A, Ormaasen, V, Knysz, B, Gasiorowski, J, Horban, A, Prokopowicz, D, Wiercinska Drapalo, A, Boron Kaczmarska, A, Pynka, M, Beniowski, M, Mularska, E, Trocha, H, Antunes, F, Mansinho, K, Maltez, F, Duiculescu, D, Babes, V, Streinu Cercel, A, Vinogradova, E, Rakhmanova, A, Jevtovic, D, Mokrás, M, Staneková, D, González Lahoz, J, Sanchez Conde, M, García Benayas, T, Martin Carbonero, L, Soriano, V, Clotet, B, Jou, A, Conejero, J, Ruiz, L, Tural, C, Gatell, Jm, Miró, Jm, Zamora, L, Blaxhult, A, Karlsson, A, Pehrson, P, Ledergerber, B, Francioli, P, Telenti, A, Hirschel, B, Soravia Dunand, V, Furrer, H, Kravchenko, E, Chentsova, N, Fisher, M, Brettle, R, Barton, S, Johnson, Am, Mercey, D, Murphy, M, Johnson, Ma, Weber, J, Scullard, G, Morfeldt, L, Thulin, G, Akerlund, B, Koppel, K, Flamholc, L, Håkangård, C, Moroni, M, Cargnel, A, Merli, S, Rizzardini, G, Pastecchia, C, Caggese, L, Moioli, C, Mura, Ms, Mannazzu, M, Suter, F, Manconi, Pe, Piano, P, Lo Caputo, S, Poggiom, A, Bottari, G, Pagano, G, Alessandrini, A, Scasso, A, Vincenti, A, Abbadessa, V, Mancuso, S, Alberici, F, Ruggieri, A, Arlotti, M, Ortolani, P, De Lalla, F, Tositti, G, Cassola, G, Piscopo, R, Raise, E, Ebo, F, Soscia, F, Tacconi, L, Tirelli, U, Di Gennaro, G, Santoro, D, Pusterla, L, Carosi, Giampiero, Torti, Carlo, Cadeo, G, Bertelli, D, Carnevale, G, Galloni, D, Filice, G, Bruno, R, Di Perri, G, Arnaudo, I, Caramello, P, Orofino, Gc, Soranzo, Ml, Bonasso, M, Quirino, T, Melzi, S, Chiodo, F, Colangeli, V, Magnani, G, Ursitti, M, Menichetti, F, Martinelli, C, Mussini, C, Ghinelli, F, Sighinolfi, L, Coronado, O, Ballardini, G, Rizzo, E, Montroni, M, Braschi, Mc, Petrelli, E, Cioppi, A, Cauda, R, De Luca, A, Petrosillo, N, Noto, P, Bontempo, G, Acinapura, A, Antonucci, G, De Longis, P, Lichtner, M, Pastore, G, Ladisa, N, Viglietti, R, Piazza, M, Nappa, S, Abrescia, N, De Marco, M, Colomba, A, Prestileo, T, De Stefano, C, La Gala, A, Cosco, L, Scerbo, A, Grima, P, Tundo, P, Vecchiet, J, D'Alessandro, M, Grisorio, B, Ferrara, S, Caissotti, C, Dellamonica, P, Bentz, L, Bernard, E, De Salvador Guillouet, F, Durant, J, Mondain Miton, V, Perbost, I, Prouvost Keller, B, Pugliese, P, Rahelinirina, V, Roger, Pm, Vandenbos, F, Battegay, M, Bernasconi, E, Böni, J, Bucher, H, Bürgisser, P, Cattacin, S, Cavassini, M, Dubs, R, Egger, M, Elzi, L, Erb, P, Fischer, M, Flepp, M, Fontana, A, Furrer, Hj, Gorgievski, M, Günthard, H, Kaiser, L, Kind, C, Klimkait, T, Lauper, U, Opravil, M, Paccaud, F, Pantaleo, G, Perrin, L, Piffaretti, Jc, Rudin, C, Schmid, P, Schüpbach, J, Speck, R, Trkola, A, Vernazza, P, and Yerly, S.
- Published
- 2008
12. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
- Author
-
D:A:D Study Group, Sabin, Ca, Worm, Sw, Weber, R, Reiss, P, El Sadr, W, Dabis, F, De Wit, S, Law, M, D'Arminio Monforte, A, Friis Møller, N, Kirk, O, Pradier, C, Weller, I, Phillips, An, Collaborators: Collins S, Lundgren J. D., El Sadr WM, Phillips, A, Rosseau, F, Storfer, Sp, Weber, I, Lundgren, Jd, Sjøl, A, Sawitz, A, Rickenbach, M, Pezzotti, P, Krum, E, Gras, L, Balestre, E, Sundström, A, Poll, B, Fontas, E, Torres, F, Petoumenos, K, Kjaer, J, Hammer, S, Neaton, J, de Wolf, F, Zaheri, S, Bronsveld, W, Hillebrand Haverkort ME, Prins, Jm, Bos, Jc, Eeftinck Schattenkerk JK, Geerlings, Se, Godfried, Mh, Lange, Jm, van Leth FC, Lowe, Sh, van der Meer JT, Nellen, Fj, Pogány, K, van der Poll, T, Ruys, Ta, Sankatsing, Steingrover, R, van Twillert, G, van der Valk, M, van Vonderen MG, Vrouenraets, Sm, van Vugt, M, Wit, Fw, van Eeden, A, ten Veen JH, van Dam PS, Roos, Jc, Brinkman, K, Frissen, Ph, Weigel, Hm, Mulder, Jw, van Gorp EC, Meenhorst, Pl, Mairuhu, At, Veenstra, J, Danner, Sa, Van Agtmael MA, Claessen, Fa, Perenboom, Rm, Rijkeboer, A, van Vonderen, M, Richter, C, van der Berg, J, van Leusen, R, Vriesendorp, R, Jeurissen, Fj, Kauffmann, Rh, Koger, El, Bravenboer, B, ten Napel CH, Kootstra, Gj, Sprenger, Hg, Miesen, Wm, Doedens, R, Scholvinck, Eh, ten Kate RW, van Houte DP, Polee, M, Kroon, Fp, van den Broek, van Dissel JT, Schippers, Ef, Schreij, G, van de Geest, S, Verbon, A, Koopmans, Pp, Keuter, M, Post, F, van der Ven AJ, van der Ende ME, Gyssens, Ic, van der Feltz, M, den Hollander JG, de Marie, S, Nouwen, Jl, Rijnders, Bj, de Vries TE, Juttmann, Jr, van de Heul, C, van Kasteren ME, Elisabeth, St, Schneider, Mm, Bonten, Mj, Borleffs, Jc, Ellerbroek, Pm, Hoepelman, Im, Jaspers, Ca, Schouten, I, Schurink, Ca, Blok, Wl, Tanis, Aa, Groeneveld, Ph, Salamon, R, Beylot, J, Dupon, M, Le Bras, M, Pellegrin, Jl, Ragnaud, Jm, Chêne, G, Jacqmin Gadda, H, Thiébaut, R, Lawson Ayayi, S, Lavignolle, V, Blaizeau, Mj, Decoin, M, Formaggio, Am, Delveaux, S, Labarerre, S, Uwamaliya, B, Vimard, E, Merchadou, L, Palmer, G, Touchard, D, Dutoit, D, Pereira, F, Boulant, B, Morlat, P, Bernard, N, Bonarek, M, Bonnet, F, Coadou, B, Gelie, P, Jaubert, D, Nouts, C, Lacoste, D, Dutronc, H, Cipriano, G, Lafarie, S, Chossat, I, Lacut, Jy, Leng, B, Mercié, P, Viallard, Jf, Faure, I, Rispal, P, Cipriano, C, Tchamgoué, S, Djossou, F, Malvy, D, Pivetaud, Jp, Chambon, D, De La Taille, C, Galperine, T, Neau, D, Ochoa, A, Beylot, C, Doutre, Ms, Bezian, Jh, Moreau, Jf, Taupin, Jl, Conri, C, Constans, J, Couzigou, P, Castera, L, Fleury, H, Lafon, Me, Masquelier, B, Pellegrin, I, Trimoulet, P, Moreau, F, Mestre, C, Series, C, Taytard, A, Anderson, J, Cortossis, P, Hoy, J, Watson, K, Roth, N, Bloch, M, Franic, T, Baker, D, Mcfarlane, R, Carr, A, Cooper, D, Chuah, J, Fankhauser, W, Mallal, S, Forsdyke, C, Calvo, G, Mateu, S, Domingo, P, Sambeat, Ma, Gatel, J, Del Cacho, E, Cadafalch, J, Fuster, M, Codina, C, Sirera, G, Vaqué, A, Clumeck, N, Gerard, M, Kabeya, K, Konopnicki, D, Libois, A, Payen, Mc, Van Laethem, Y, Bartsch, G, Thompson, G, Wentworth, D, Luskin Hawk, R, Telzak, E, Abrams, Di, Cohn, D, Markowitz, N, Arduino, R, Mushatt, D, Friedland, G, Perez, G, Tedaldi, E, Fisher, E, Gordin, F, Crane, Lr, Sampson, J, Baxter, J, Mocroft, A, Vetter, N, Karpov, I, Vassilenko, A, Colebunders, R, Machala, L, Rozsypal, H, Sedlacek, D, Nielsen, J, Benfield, T, Gerstoft, J, Katzenstein, T, Hansen, Ab, Skinhøj, P, Pedersen, C, Zilmer, K, Katlama, C, Viard, Jp, Girard, Pm, Saint Marc, T, Vanhems, P, Dietrich, M, Manegold, C, van Lunzen, J, Stellbrink, Hj, Staszewski, S, Bieckel, M, Goebel, Fd, Fätkenheuer, G, Rockstroh, J, Schmidt, Re, Kosmidis, J, Gargalianos, P, Sambatakou, H, Perdios, J, Panos, G, Filandras, A, Banhegyi, D, Mulcahy, F, Yust, I, Burke, M, Turner, D, Pollack, S, Hassoun, J, Sthoeger, Z, Maayan, S, Vella, S, Chiesi, A, Arici, C, Pristerá, R, Mazzotta, F, Gabbuti, A, Esposito, R, Bedini, A, Chirianni, A, Montesarchio, E, Vullo, V, Santopadre, P, Narciso, P, Antinori, A, Franci, P, Zaccarelli, M, Lazzarin, A, Castagna, A, Viksna, L, Chaplinskas, S, Hemmer, R, Staub, T, Bruun, J, Maeland, A, Ormaasen, V, Knysz, B, Gasiorowski, J, Horban, A, Prokopowicz, D, Wiercinska Drapalo, A, Boron Kaczmarsk, A, Pynka, M, Beniowski, M, Mularska, E, Trocha, H, Antunes, A, Mansinho, K, Maltez, F, Duiculescu, D, Streinu Cercel, A, Vinogradova, E, Rakhmanova, A, Jevtovic, D, Mokrás, M, Staneková, D, González Lahoz, J, Sanchez Conde, M, García Benayas, T, Martin Carbonero, L, Soriano, V, Clotet, B, Jou, A, Conejero, J, Ruiz, L, Tural, C, Gatell, Jm, Miró, Jm, Zamora, L, Gutierrez, M, Mateo, G, Blaxhult, A, Karlsson, A, Pehrson, P, Ledergerber, B, Francioli, P, Telenti, A, Hirschel, B, Soravia Dunand, V, Furrer, H, Kravchenko, E, Chentsova, N, Fisher, M, Brettle, R, Barton, S, Johnson, Am, Mercey, D, Murphy, M, Johnson, Ma, Weber, J, Scullard, G, Morfeld, L, Thulin, G, Akerlund, B, Koppel, K, Flamholc, L, Håkangård, C, d'Arminio Monforte, A, Moroni, M, Cargnel, A, Merli, S, Vigevani, Gm, Pastecchia, C, Morsica, G, Caggese, L, Moioli, C, Mura, Ms, Mannazzu, M, Suter, F, Manconi, Pe, Piano, P, Lo Caputo, S, Poggio, A, Bottari, G, Pagano, G, Alessandrini, A, Scasso, A, Abbadessa, V, Mancuso, S, Alberici, F, Ruggieri, A, Arlotti, M, Ortolani, P, De Lalla, F, Tositti, G, Cassola, G, Piscopo, R, Raise, E, Ebo, F, Soscia, F, Tacconi, L, Tirelli, U, Cinelli, R, Santoro, D, Pusterla, L, Carosi, Giampiero, Torti, Carlo, Cadeo, G, Bertelli, D, Carnevale, G, Citterio, P, Filice, G, Bruno, R, Di Perri, G, Arnaudo, I, Caramello, P, Orofino, Gc, Soranzo, Ml, Bonasso, M, Rizzardini, G, Melzi, S, Chiodo, F, Colangeli, V, Magnani, G, Ursitti, M, Menichetti, F, Martinelli, C, Mussini, C, Ghinelli, F, Sighinolfi, L, Coronado, O, Ballardini, G, Rizzo, E, Montroni, M, Braschi, Mc, Petrelli, E, Cioppi, A, Cauda, R, De Luca, A, Petrosillo, N, Noto, P, Bontempo, G, Acinapura, R, Antonucci, G, De Longis, P, Lichtner, M, Pastore, G, Ladisa, N, Viglietti, R, Piazza, M, Nappa, S, Abrescia, N, De Marco, M, Colomba, A, Prestileo, T, De Stefano, C, La Gala, A, Cosco, L, Scerbo, A, Grima, P, Tundo, P, Vecchiet, J, D'Alessandro, M, Grisorio, B, Ferrara, S, Caissotti, C, Dellamonica, P, Bentz, L, Bernard, E, De Salvador Guillouet, F, Durant, J, Mondain Miton, V, Perbost, I, Prouvost Keller, B, Pugliese, P, Rahelinirina, V, Roger, Pm, Vander, F, Battegay, M, Bernasconi, E, Böni, J, Buche, H, Bürgisser, P, Cattacin, S, Cavassini, M, Dubs, R, Egger, M, Elzi, L, Erb, P, Fischer, M, Flepp, M, Fontana, A, Furrer, Hj, Gorgievski, M, Günthard, H, Kaiser, L, Kind, C, Klimkait, T, Lauper, U, Opravil, M, Paccaud, F, Pantaleo, G, Perrin, L, Piffaretti, Jc, Rudin, C, Schmid, P, Schüpbach, J, Speck, R, Trkola, A, Vernazza, P, and Yerly, S.
- Published
- 2008
13. What?s New in HIV/AIDS
- Author
-
Rika Draenert and Goebel Fd
- Subjects
AIDS Vaccines ,CD4-Positive T-Lymphocytes ,Microbiology (medical) ,Protective immunity ,medicine.medical_treatment ,Developing country ,HIV Infections ,Dendritic Cells ,General Medicine ,Immunotherapy ,medicine.disease ,Asymptomatic ,Infectious Diseases ,Immune system ,Acquired immunodeficiency syndrome (AIDS) ,Immunity ,Antibody Formation ,Immunology ,medicine ,Humans ,medicine.symptom ,Antigens, Viral ,T-Lymphocytes, Cytotoxic - Abstract
In the face of a global epidemic of HIV/AIDS with the majority of individuals living in the developing countries, a protective vaccine seem the foremost goal. As this is not within imminent reach, the other option would be immunotherapy that prolongs the asymptomatic phase of infection. The basis for such a therapy is to understand the correlates of protective immunity against HIV. Here we present the most recent advances regarding selected parts of the immune response towards HIV.
- Published
- 2004
- Full Text
- View/download PDF
14. HIV nef protein is a potential candidate vaccine against AIDS
- Author
-
Cosma, A, Burch, D, Calarota, S, Kleinschimdt, A, Buhler, S, Sidoti, Antonina, Amato, Aldo, Sutter, G, Wahren, B, Goebel, Fd, and Erflle, V.
- Published
- 2002
15. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study
- Author
-
UCL - Autre, Lundgren, JD., Mocroft, A., Gatell, JM., Ledergerber, B., Monforte, AD, Hermans, P., Goebel, FD., Blaxhult, A., Kirk, O., Phillips, Andrew, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, UCL - Autre, Lundgren, JD., Mocroft, A., Gatell, JM., Ledergerber, B., Monforte, AD, Hermans, P., Goebel, FD., Blaxhult, A., Kirk, O., Phillips, Andrew, and 40th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Abstract
The risk of clinical progression for human immunodeficiency virus (HIV)-infected persons receiving treatment with highly active antiretroviral therapy (HAART) is poorly defined. From an inception cohort of 8457 HIV-infected persons, 2027 patients who started HAART during prospective follow-up were examined. Results were validated in another 2 groups of patients (n = 1946 and n = 1442). In total, 200 patients (9.9%) experienced clinical progression during 5177 person-years (incidence, 3.9/100 years). The most recently measured CD4 cell count, virus load, and hemoglobin level all were independently related to the risk of clinical progression, as was a diagnosis of severe AIDS before the start of HAART. On the basis of these findings, a scoring system was derived (range, 0-17). A single unit increase in the score was associated with a 38% increased risk of clinical progression (relative hazard, 1.38; 95% confidence interval, 1.33-1.43; P < .0001). The scoring system was validated with remarkably good agreement in the 2 other cohorts. This system can be used in patient and resource management.
- Published
- 2002
16. P18-04. MVA-nef vaccination induces specific T-cell responses exerting functions associated with non-progressive disease in HIV-1 infected individuals
- Author
-
Kutscher, S, primary, Allgayer, S, additional, Dembek, CJ, additional, Bogner, JR, additional, Goebel, FD, additional, Erfle, V, additional, and Cosma, A, additional
- Published
- 2009
- Full Text
- View/download PDF
17. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients.
- Author
-
Phillips, AN, Pradier, C, Lazzarin, A, Clotet, B, Goebel, FD, Hermans, P, Antunes, F, Ledergerber, B, Kirk, O, Lundgren, Jens Dilling, Phillips, AN, Pradier, C, Lazzarin, A, Clotet, B, Goebel, FD, Hermans, P, Antunes, F, Ledergerber, B, Kirk, O, and Lundgren, Jens Dilling
- Published
- 2001
18. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type
- Author
-
Bogner, JR, primary, Lutz, B, additional, Klein, HG, additional, Pollerer, C, additional, Troendle, U, additional, and Goebel, FD, additional
- Published
- 2004
- Full Text
- View/download PDF
19. Primary and secondary prophylaxis for Pneumocystis carinii related complications in HIV patients
- Author
-
Held, M, primary and Goebel, FD, additional
- Published
- 1996
- Full Text
- View/download PDF
20. Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy
- Author
-
Cozzi-Lepri, Alessandro, Ruiz, Lidia, Loveday, Clive, Phillips, Andrew N, Clotet, Bonaventura, Reiss, Peter, Ledergerber, Bruno, Holkmann, Christian, Staszewski, Schlomo, Lundgren, Jens D, Losso, M, Duran, A., Vetter, N, Clumeck, N, De Wit, S, Poll, B, Colebunders, R, Machala, L, Rozsypal, H, Nielsen, J, Lundgren, J, Kirk, O, Olsen, CH, Gerstoft, J, Katzenstein, T, Hansen, ABE, Skinhøj, P, Pedersen, C, Zilmer, K, Rauka, M, Katlama, C, De Sa, M, Viard, J-P, Marc, T Saint, Vanhems, P, Pradier, C, Dietrich, M, Manegold, C, Van Lunzen, J, Stellbrink, H-J, Miller, V, Staszewski, S, Goebel, FD, Salzberger, B, Rockstroh, J, Schmidt, RE, Stoll, M, Kosmidis, J, Gargalianos, P, Sambatakou, H, Perdios, J, Panos, G, Banhegyi, D, Mulcahy, F, Yust, I, Burke, M, Pollack, S, Hassoun, J, Sthoeger, Z, Maayan, S, Vella, S, Chiesi, A, Arici, C, Pristerá, R, Mazzotta, F, Gabbuti, A, Esposito, R, Bedini, A, Chirianni, A, Montesarchio, E, Vullo, V, Santopadre, P, Narciso, P, Antinori, A, Franci, P, Zaccarelli, M, Lazzarin, A, Castagna, A, Monforte, D'Arminio, Viksna, L, Rozentale, B, Chaplinskas, S, Hemmer, R, Staub, T, Reiss, P, Bruun, J, Maeland, A, Ormaasen, V, Knysz, B, Gasiorowski, J, Horban, A, Prokopowicz, D, Drapalo, A Wiercinska, Kaczmarska, A Boron, Pynka, M, Beniowski, M, Trocha, H, Smiatacz, T, Antunes, F, Mansinho, K, Maltez, F, Duiculescu, D, Babes, V, Cercel, A Streinu, Mokrás, M, Staneková, D, González-Lahoz, J, Diaz, B, García-Benayas, T, Carbonero, L Martin, Soriano, V, Clotet, B, Jou, A, Conejero, J, Tural, C, Gatell, JM, Miró, JM, Zamora, L, Blaxhult, A, Karlsson, A, Pehrson, P, Ledergerber, B, Weber, R, Francioli, P, Hirschel, B, Schiffer, V, Furrer, H, Chentsova, N, Barton, S, Johnson, AM, Mercey, D, Youle, M, Phillips, A, Johnson, MA, Mocroft, A, Murphy, M, Weber, J, Scullard, G, Fisher, M, Brettle, R, Loveday, C, Clotet, B, Ruiz, L, Antunes, F, Blaxhult, A, Clumeck, N, Gatell, J, Horban, A, Johnson, A, Katlama, C, Ledergerber, B, Loveday, C, Phillips, A, Reiss, P, Vella, S, Lundgren, J, Gjørup, I, Kirk, O, Moeller, N Friis, Mocroft, A, Lepri, A Cozzi, Bannister, W, Mollerup, D, Nielsen, M, Hansen, A, Kristensen, D, Kolte, L, Hansen, L, and Kjær, J
- Abstract
Background Studies have suggested that HIV-1 may develop thymidine analogue mutations (TAMs) by one of two distinct pathways – the TAM1 pathway (including mutations 41L, 210W and 215Y) or the TAM2 pathway (including mutations 67N, 70R and 219E/Q) – under the pressure of a not fully suppressive thymidine-analogue-containing regimen.Methods Frozen plasma samples stored in the EuroSIDA repository were selected and sent to two central laboratories for genotypic analysis. We considered 733 patients with at least one genotypic test showing =1 TAMs (the first of these tests in chronological order was used). TAM1 and TAM2 genotypic profiles were defined in accordance with previous literature. Statistical modelling involved logistic regression and linear regression analysis for censored data.Results The observed frequencies of patterns classifiable as TAM1 or TAM2 profiles were markedly higher than the probabilities of falling into these classifications by chance alone. The chance of detecting a TAM2 profile increased by 25% per additional year of exposure to zidovudine. We found that mutations 67N and 184V were not associated with a particular TAM profile. In the presence of TAM2 profiles, the adjusted mean difference in the 6-month viral reduction was 0.96 log10copies/ml (95% confidence interval: 0.20; 1.73) higher in patients who started stavudine-containing regimens instead of zidovudine-containing regimens.Conclusions This study provides evidence that the suggested TAM clustering is a real phenomenon and that it may be driven by which thymidine analogue the patients has used. In patients with TAM2-resistant viruses, stavudine appears to retain greater viral activity than zidovudine.
- Published
- 2005
- Full Text
- View/download PDF
21. AIDS-Erkrankung und Psychopathologie - Beobachtungen aus dem psychiatrischen Konsiliardienst in einer internistischen Klinik
- Author
-
Goebel Fd, Naber D, and Andreas Erfurth
- Subjects
Service (business) ,medicine.medical_specialty ,Internal medicine clinic ,business.industry ,education ,Disease ,medicine.disease ,University hospital ,Psychiatry and Mental health ,Health services ,Neurology ,Psychiatric consultation ,Acquired immunodeficiency syndrome (AIDS) ,Family medicine ,medicine ,Neurology (clinical) ,business ,health care economics and organizations ,Psychopathology - Abstract
The majority of HIV-infected inpatients are treated in departments of internal medicine. For the conditions of the west-german health service it was studied, if and how psychiatric symptoms of HIV-positive inpatients of a University Hospital for internal medicine require a psychiatrist. The evaluation of the suicide risk and psychopharmacological treatment of depressive syndromes were the most frequent reasons to ask for a psychiatrist. It became evident, that by means of a psychiatric consultation service, treatment of psychiatric complications in HIV-infection is feasible in a department of internal medicine.
- Published
- 1989
- Full Text
- View/download PDF
22. Adaptation of Red Cell Enzymes and Intermediates in Metabolic Disorders
- Author
-
Hausmann L, Schneider J, Neitzert A, Goebel Fd, and Goebel Km
- Subjects
medicine.medical_specialty ,Erythrocytes ,endocrine system diseases ,Phosphofructokinase-1 ,Pyruvate Kinase ,Glutathione reductase ,Hyperlipidemias ,Glucosephosphate Dehydrogenase ,Pentose phosphate pathway ,Hypoglycemia ,Hyperthyroidism ,Biochemistry ,chemistry.chemical_compound ,Hexokinase ,Internal medicine ,Diabetes Mellitus ,medicine ,Humans ,Glycolysis ,chemistry.chemical_classification ,Glucose-6-Phosphate Isomerase ,nutritional and metabolic diseases ,Glutathione ,Glucose phosphate ,medicine.disease ,Glutathione Reductase ,Endocrinology ,Enzyme ,chemistry ,Hyperglycemia - Abstract
The metabolic activity of the red cell glycolytic pathway hexose monophosphate shunt (HMP) with dependent glutathione system was studied in patients with hyperthyroidism (n = 10), hyperlipoproteinemia (n = 16), hypoglycemia (n = 25) and hyperglycemia (n = 23). In uncontrolled diabetics and patients with hyperthyroidism the mean value of glucose phosphate isomerase (GPI), glucose-6-phosphate dehydrogenase (G-6-PD), glutathione reductase (GR) was increased, whereas these enzyme activities were reduced in patients with hypoglycemia. Apart from a few values of hexokinase (HK) which were lower than normal the results in hyperlipoproteinemia patients remained essentially unchanged, including the intermediates such as 2,3-diphosphoglycerate (2,3-DPG), adenosine triphosphate (ATP) and reduced glutathione (GSH). While increased rates of 2,3-DPG and ATP in hypoglycemia patients were obtained, these substrates were markedly reduced in diabetics.
- Published
- 1975
- Full Text
- View/download PDF
23. Avanti 3: A Randomized, Double-Blind Trial to Compare the Efficacy and Safety of Lamivudine plus Zidovudine versus Lamivudine plus Zidovudine plus Nelfinavir in HIV-1-Infected Antiretroviral-Naive Patients
- Author
-
Gartland, Martin, Clumeck, N, Cooper, DA, Gatell, J, Gazzard, B, Gerstoft, J, Goebel, F, Lange, J, Montaner, J, Reiss, P, Rozenbaum, W, Vella, S, Cooper, DA, Haberl, M, Clumeck, N, Luyts, D, Montaner, J., Rachlis, A, Marina, R, Gerstoft, J, Mathiesen, L, Soelberg, U, Molina, J-M, Pialloux, G, Rozenbaum, W, Cosby, C, Goebel, FD, Staszewski, S, Hug, M, Milazzo, F, Moroni, M, Panebianco, R, Clotet, B, Artigas, JM Gatell, GonzalezLahoz, J, Leal, M, Gandarias, B, Gazzard, B, Johnson, M, Watkins, K, Page, V, Sandstrom, E, Darbyshire, J, Petersen, A, Athisegaran, R, Coughlan, M, Fiddian, P, Gartland, M, Harrigan, R, Henry, T, Larder, B, Maguire, M, Millard, J, Moore, S, Patel, K, Shortino, D, Tisdale, M, Vafidis, I, and Yeo, J
- Abstract
The objective of our randomized, multicentre, double-blind, placebo-controlled study was to investigate the safety, tolerability, and antiretroviral and immunological effect of double and triple combination therapy regimens. A total of 105 antiretroviral therapy-naive patients were randomized to receive either zidovudine (300 mg twice per day) plus lamivudine (150 mg twice per day) plus nelfinavir placebo (three times per day) (n=52), or zidovudine/lamivudine (dose as before) plus nelfinavir (750 mg three times per day) (n=53) for 28 weeks. After this time, patients were allowed to switch to open-label zidovudine/lamivudine/nelfinavir. The overall log10reduction from baseline in plasma HIV-1 RNA was significantly greater in the zidovudine/lamivudine/nelfinavir group than the zidovudine/lamivudine group (P=0.001; median treatment difference, –1.01 log10copies/ml; 95% confidence interval –1.23 to –0.79), as measured by the average area under the curve minus baseline over 28weeks. Increases from baseline in CD4 cell counts were statistically significantly greater in the zidovudine/lamivudine/nelfinavir group (101.5 cells/ml) than the zidovudine/lamivudine group (47.0 cells/ml; P=0.027) at week 28.Of note, the addition of nelfinavir from weeks 28–52 led to an increase in the proportion of subjects with plasma HIV-1 RNA <400 copies/ml from 17% (9/52 patients on zidovudine/lamivudine) to 50% (13/26 patients who switched to zidovudine/lamivudine/nelfinavir). Incidence of drug-related adverse events was similar in the two groups, except for nausea (more common in zidovudine/lamivudine group; 40 versus 17%) and diarrhoea (more common in zidovudine/lamivudine/nelfinavir group; 45 versus 14%). In conclusion, our study confirms the efficacy of triple combination therapy with two nucleoside analogues and a protease inhibitor compared with double-nucleoside therapy. Interestingly, the addition of nelfinavir to zidovudine/lamivudine, even after 6 months of double nucleoside therapy, led to a substantial virological benefit that was sustained over 24weeks in a subset of patients.
- Published
- 2001
- Full Text
- View/download PDF
24. AIDS, multicentric Castleman's disease, and plasmablastic leukemia: report of a long-term survival.
- Author
-
Horster S, Jung C, Zietz C, Cohen CD, Siebeck M, and Goebel FD
- Abstract
Plasmablastic leukemia (PL) as a complication of human herpes virus 8 (HHV8)-associated Castleman's disease is marked by a rapid and fatal outcome. In patients with AIDS, survival of 7 to 14 days after diagnosis has been reported. Prompt splenectomy and chemotherapy might lead to a significant survival benefit. Here we report a case of long-term survival in a patient with AIDS and multicentric Castleman's disease (MCD) complicated by PL. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
25. Mönckeberg's sclerosis after sympathetic denervation in diabetic and non-diabetic subjects
- Author
-
Füessl Hs and Goebel Fd
- Subjects
Male ,medicine.medical_specialty ,Diabetic neuropathy ,Arteriosclerosis ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Sympathetic Denervation ,Calcinosis ,Diabetes mellitus ,Internal Medicine ,medicine ,Humans ,Sympathectomy ,Aged ,Medial arterial calcification ,business.industry ,Foot ,Incidence (epidemiology) ,Middle Aged ,medicine.disease ,Surgery ,Radiography ,Female ,business ,Diabetic Angiopathies ,Calcification - Abstract
Medial arterial calcification is frequently seen in diabetic patients with severe diabetic neuropathy. Sixty patients (19 diabetic and 41 non-diabetic) were examined radiologically for typical Mönckeberg's sclerosis of feet arteries 6-8 years after uni- or bilateral lumbar sympathectomy. Fifty-five out of 60 patients (92%) revealed medial calcification. This calcification was observed in both feet of 93% of patients, who had undergone bilateral operation. After unilateral sympathectomy the incidence of calcified arteries on the side of operation was significantly higher than that on the contralateral side (88% versus 18%, p less than 0.01). Although diabetic patients showed longer stretches of calcification than non-diabetic subjects, the difference was not significant in terms of incidence and length. Of 20 patients who had no evidence of calcinosis pre-operatively, 11 developed medial calcification after unilateral operation exclusively on the side of sympathectomy. In seven patients calcinosis was detected in both feet after bilateral operation. In conclusion, sympathetic denervation is one of the causes of Mönckeberg's sclerosis regardless of diabetes mellitus.
- Published
- 1983
26. AIDS and pre-AIDS mortality in the EUROSIDA study
- Author
-
Brettle, Rp, Mocroft, A., Ledergerber, B., Gatell, Jm, Hermans, P., Goebel, Fd, and Jens Lundgren
27. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America
- Author
-
Costagliola, D., Dabis, F., Monforte, Ad, Wolf, F., Egger, M., Fatkenheuer, G., Gill, J., Hogg, R., Justice, A., Ledergerber, B., Lundgren, J., May, M., Phillips, A., Reiss, P., Sabin, C., Staszewski, S., Sterne, J., Weller, I., Beckthold, B., Yip, B., Dauer, B., Fusco, J., Grabar, S., Lanoy, E., Junghans, C., Lavignolle, V., Leth, F., Pereira, E., Pezzotti, P., Schmeisser, N., Billaud, E., Boue, F., Duval, X., Duvivier, C., Enel, P., Fournier, S., Gasnault, J., Gaud, C., Gilquin, J., Khuong, Ma, Lang, Jm, Mary-Krause, M., Matheron, S., Meyohas, Mc, Pialoux, G., Poizot-Martin, I., Pradier, C., Rouveix, E., Salmon-Ceron, D., Sobel, A., Tattevin, P., Tissot-Dupont, H., Yasdanpanah, Y., Aronica, E., Tirard-Fleury, V., Tortay, I., Abgrall, S., Guiguet, M., Leneman, H., Lievre, L., Potard, V., Saidi, S., Vilde, Jl, Leport, C., Yeni, P., Bouvet, E., Gaudebout, C., Crickx, B., Picard-Dahan, C., Weiss, L., Tisne-Dessus, D., Sicard, D., Salmon, D., Auperin, I., Viard, Jp, Roudiere, L., Delfraissy, Jf, Goujard, C., Lesprit, P., Jung, C., Meynard, Jl, Picard, O., Desplanque, N., Cadranel, J., Mayaud, C., Rozenbaum, W., Bricaire, F., Katlama, C., Herson, S., Simon, A., Decazes, Jm, Molina, Jm, Clauvel, Jp, Gerard, L., Widal, Ghlf, Sellier, P., Diemer, M., Dupont, C., Berthe, H., Saiag, P., Mortier, L., Mortier, E., Chandemerle, C., Truchis, P., Bentata, M., Honore, P., Tassi, S., Jeantils, V., Mechali, D., Taverne, B., Laurichesse, H., Gourdon, F., Lucht, F., Fresard, A., Faller, Jp, Eglinger, P., Bazin, C., Verdon, R., Peyramond, D., Boibieux, A., Touraine, Jl, Livrozet, Jm, Trepo, C., Cotte, L., Ravaux, I., Delmont, Jp, Moreau, J., Gastaut, Ja, Soubeyrand, J., Retornaz, F., Blanc, Pa, Allegre, T., Galinier, A., Ruiz, Jm, Lepeu, G., Granet-Brunello, P., Pelissier, L., Esterni, Jp, Nezri, M., Cohen-Valensi, R., Laffeuillade, A., Chadapaud, S., Reynes, J., May, T., Rabaud, C., Raffi, F., Pugliese, P., Michelet, C., Arvieux, C., Caron, F., Borsa-Lebas, F., Fraisse, P., Massip, P., Cuzin, L., Arlet-Suau, E., Legrand, Mft, Sobesky, M., Pradinaud, R., Guyon, F., Contant, M., Montroni, M., Scalise, G., Braschi, Mc, Aviano, Ar, Tirelli, U., Cinelli, R., Pastore, G., Ladisa, N., Minafra, G., Suter, F., Arici, C., Chiodo, F., Colangeli, V., Fiorini, C., Coronado, O., Carosi, G., Cadeo, Gp, Torti, C., Minardi, C., Bertelli, D., Rizzardini, G., Melzi, S., Manconi, Pe, Catanzaro, Pp, Cosco, L., Scerbo, A., Vecchiet, J., D Alessandro, M., Santoro, D., Pusterla, L., Carnevale, G., Citterio, P., Vigano, P., Mena, M., Ghinelli, F., Sighinolfi, L., Leoncini, F., Mazzotta, F., Pozzi, M., Lo Caputo, S., Angarano, G., Grisorio, B., Saracino, A., Ferrara, S., Grima, P., Tundo, P., Pagano, G., Cassola, G., Alessandrini, A., Piscopo, R., Toti, M., Chigiotti, S., Soscia, F., Tacconi, L., Orani, A., Perini, P., Scasso, A., Vincenti, A., Chiodera, F., Castelli, P., Scalzini, A., Palvarini, L., Moroni, M., Lazzarin, A., Cargnel, A., Vigevani, Gm, Caggese, L., Repetto, D., Galli, A., Merli, S., Pastecchia, C., Moioli, Mc, Esposito, R., Mussini, C., Abrescia, N., Chirianni, A., Izzo, Cm, Piazza, M., Marco, M., Viglietti, R., Manzillo, E., Nappa, S., Colomba, A., Abbadessa, V., Prestileo, T., Mancuso, S., Ferrari, C., Pizzaferri, P., Filice, G., Minoli, L., Bruno, R., Novati, S., Baldelli, F., Tinca, M., Petrelli, E., Cioppi, A., Alberici, F., Ruggieri, A., Menichetti, F., Martinelli, C., Stefano, C., La Gala, A., Ballardini, G., Rizzo, E., Magnani, G., Ursitti, Ma, Arlotti, M., Ortolani, P., Cauda, R., Dianzani, F., Ippolito, G., Antinori, A., Antonucci, G., D Elia, S., Narciso, P., Petrosillo, N., Vullo, V., Luca, A., Bacarelli, A., Zaccarelli, M., Acinapura, R., Longis, P., Brandi, A., Trotta, Mp, Noto, P., Lichtner, M., Capobianchi, MR, Carletti, F., Girardi, E., Rezza, G., Mura, Ms, Mannazzu, M., Caramello, P., Di Perri, G., Soranzo, Ml, Orofino, Gc, Arnaudo, I., Bonasso, M., Grossi, Pa, Basilico, C., Poggio, A., Bottari, G., Raise, E., Ebo, F., Lalla, F., Tositti, G., Resta, F., Loso, K., Lepri, Ac, Battegay, M., Bernasconi, E., Boni, J., Bucher, H., Burgisser, P., Cattacin, S., Cavassini, M., Dubs, R., Elzi, L., Erb, P., Fantelli, K., Fischer, M., Flepp, M., Fontana, A., Francioli, P., Furrer, H., Gorgievski, M., Hirschel, B., Kaiser, L., Kind, C., Klimkait, T., Lauper, U., Opravil, M., Paccaud, F., Pantaleo, G., Perrin, L., Piffaretti, Jc, Rickenbach, M., Rudin, C., Schmid, P., Schupbach, J., Speck, R., Telenti, A., Trkola, A., Vernazza, P., Weber, R., Yerly, S., Bronsveld, W., Hillebrand-Haverkort, Me, Prins, Jm, Bos, Jc, Schattenkerk, Jkme, Geerlings, Se, Godfried, Mh, Lange, Jma, Leth, Fc, Lowe, Sh, Meer, Jtm, Nellen, Fjb, Pogany, K., Poll, T., Ruys, Ta, Sankatsing, S., Steingrover, R., Twillert, G., Valk, M., Vonderen, Mga, Vrouenraets, Sme, Vugt, M., Wit, Fwmn, Kuijpers, Tw, Pajkrt, D., Scherpbier, Hj, Eeden, A., Ten Veen, Jh, Dam, Ps, Roos, Jc, Brinkman, K., Frissen, Phj, Weigel, Hm, Mulder, Jw, Gorp, Ecm, Meenhorst, Pl, Mairuhu, Ata, Ziekenhuis, S., Veenstra, J., Danner, Sa, Agtmael, Ma, Claessen, Fap, Perenboom, Rm, Rijkeboer, A., Vonderen, M., Richter, C., Berg, J., Leusen, R., Vriesendorp, R., Jeurissen, Fjf, Kauffmann, Rh, Koger, Elw, Bravenboer, B., Ten Napel, Chh, Kootstra, Gj, Sprenger, Hg, Miesen, Wmaj, Doedens, R., Scholvinck, Eh, Ten Kate, Rw, Houte, Dpf, Polee, M., Kroon, Fp, van den Broek, Dissel, Jt, Schippers, Ef, Schreij, G., Geest, Sv, Verbon, A., Koopmans, Pp, Keuter, M., Post, F., Ven, Ajam, Ende, Me, Gyssens, Ic, Feltz, M., Den Hollander, Jg, Marie, S., Nouwen, Jl, Rijnders, Bja, Vries, Tems, Driessen, G., Groot, R., Hartwig, N., Juttmann, Jr, Heul, C., Kasteren, Mee, Schneider, Mme, Bonten, Mjm, Borleffs, Jcc, Ellerbroek, Pm, Hoepelman, Im, Jaspers, Cajj, Schouten, I., Schurink, Cam, Geelen, Spm, Wolfs, Tfw, Blok, Wl, Tanis, Aa, Groeneveld, Php, Klinieken-Zwolle, I., Back, Nkt, Bakker, Meg, Berkhout, B., Jurriaans, S., Cuijpers, T., Rietra, Pjgm, Roozendaal, Kj, Pauw, W., Zanten, Ap, Blomberg, Bme, Savelkoul, P., Swanink, Cma, Franck, Pfh, Lampe, As, Hendriks, R., Schirm, J., Veenendaal, D., Storm, H., Weel, J., Zeijl, H., Kroes, Acm, Claas, Hcj, Bruggeman, Camva, Goossens, Vj, Galama, Jmd, Melchers, Wjg, Poort, Yag, Doornum, Gjj, Niesters, Mg, Osterhaus, Adme, Schutten, M., Buiting, Agm, Swaans, Cam, Boucher, Cab, Boel, E., Jansz, Af, Losso, M., Duran, A., Vetter, N., Karpov, I., Vassilenko, A., Clumeck, N., Wit, S., Poll, B., Colebunders, R., Machala, L., Rozsypal, H., Dalibor Sedlacek, Nielsen, J., Benfield, T., Kirk, O., Gerstoft, J., Katzenstein, T., Hansen, Abe, Skinhoj, P., Pedersen, C., Zilmer, K., Girard, Pm, Saint-Marc, T., Vanhems, P., Dietrich, M., Manegold, C., Lunzen, J., Stellbrink, Hj, Bickel, M., Goebel, Fd, Rockstroh, J., Schmidt, R., Kosmidis, J., Gargalianos, P., Sambatakou, H., Perdios, J., Panos, G., Filandras, A., Karabatsaki, E., Banhegyi, D., Mulcahy, F., Yust, I., Turner, D., Burke, M., Pollack, S., Hassoun, G., Sthoeger, Z., Maayan, S., Chiesi, A., Borghi, R., Pristera, R., Gabbuti, A., Montesarchio, E., Iacomi, F., Finazzi, R., Viksna, L., Chaplinskas, S., Hemmer, R., Staub, T., Bruun, J., Maeland, A., Ormaasen, V., Knysz, B., Gasiorowski, J., Horban, A., Prokopowicz, D., Wiercinska-Drapalo, A., Boron-Kaczmarska, A., Pynka, M., Beniowski, M., Mularska, E., Trocha, H., Antunes, F., Valadas, E., Mansinho, K., Matez, F., Duiculescu, D., Babes, V., Streinu-Cercel, A., Vinogradova, E., Rakhmanova, A., Jevtovic, D., Mokras, M., Stanekova, D., Gonzalez-Lahoz, J., Sanchez-Conde, M., Garcia-Benayas, T., Martin-Carbonero, L., Soriano, V., Clotet, B., Jou, A., Conejero, J., Tural, C., Gatell, Jm, Miro, Jm, Blaxhult, A., Karlsson, A., Pehrson, P., Soravia-Dunand, V., Kravchenko, E., Chentsova, N., Barton, S., Johnson, Am, Mercey, D., Johnson, Ma, Mocroft, A., Murphy, M., Weber, J., Scullard, G., Fisher, M., Brettle, R., Loveday, C., Gatell, J., Johnson, A., Vella, S., Gjorup, I., Friis-Moeller, N., Cozzi-Lepri, A., Bannister, W., Mollerup, D., Podlevkareva, D., Olsen, Ch, Kjaer, J., Raffanti, S., Dieterch, D., Becker, S., Scarsella, A., Fusco, G., Most, B., Balu, R., Rana, R., Beckerman, R., Ising, T., Irek, R., Johnson, B., Hirani, A., Dejesus, E., Pierone, G., Lackey, P., Irek, C., Burdick, J., Leon, S., Arch, J., Helm, Eb, Carlebach, A., Muller, A., Haberl, A., Nisius, G., Lennemann, T., Rottmann, C., Wolf, T., Stephan, C., Mosch, M., Gute, P., Locher, L., Lutz, T., Klauke, S., Knecht, G., Doerr, Hw, Sturmer, M., Hentig, N., Jennings, B., Beylot, J., Chene, G., Dupon, M., Longy-Boursier, M., Pellegrin, Jl, Ragnaud, Jm, Salamon, R., Thiebaut, R., Lewden, C., Lawson-Ayayi, S., Mercie, P., Moreau, Jf, Moriat, P., Bernard, N., Lacoste, D., Malvy, D., Neau, D., Blaizeau, Mj, Decoin, M., Delveaux, S., Hannapier, C., Labarrere, S., Lavignolle-Aurillac, V., Uwamaliya-Nziyumvira, B., Palmer, G., Touchard, D., Balestre, E., Alioum, A., Jacqmin-Gadda, H., Morlat, P., Bonarek, M., Bonnet, F., Coadou, B., Gellie, P., Nouts, C., Bocquentin, F., Dutronc, H., Lafarie, S., Aslan, A., Pistonne, T., Thibaut, P., Vatan, R., Chambon, D., La Taille, C., Cazorla, C., Ocho, A., Castera, L., Fleury, H., Lafon, Me, Masquelier, B., Pellegrin, I., Breilh, D., Blanco, P., Loste, P., Caunegre, L., Bonnal, F., Farbos, S., Ferrand, M., Ceccaldi, J., Tchamgoue, S., Witte, S., Buy, E., Alexander, C., Barrios, R., Braitstein, P., Brumme, Z., Chan, K., Cote, H., Gataric, N., Geller, J., Guillemi, S., Harrigan, Harris, M., Joy, R., Levy, A., Montaner, J., Montessori, V., Palepu, A., Phillips, E., Phillips, P., Press, N., Tyndall, M., Wood, E., Ballinger, J., Bhagani, S., Breen, R., Byrne, P., Carroll, A., Cropley, I., Cuthbertson, Z., Drinkwater, T., Fernandez, T., Geretti, Am, Murphy, G., Ivens, D., Johnson, M., Kinloch-De Loes, S., Lipman, M., Madge, S., Prinz, B., Bell, Dr, Shah, S., Swaden, L., Tyrer, M., Youle, M., Chaloner, C., Gumley, H., Holloway, J., Puradiredja, D., Sweeney, J., Tsintas, R., Bansi, L., Fox, Z., Lampe, F., Smith, C., Amoah, E., Clewley, G., Dann, L., Gregory, B., Jani, I., Janossy, G., Kahan, M., Thomas, M., Gill, Mj, Read, R., Schmeisser, V., Voigt, K., Wasmuth, Jc, Wohrmann, A., and Antiretroviral Therapy Cohort Coll
28. KSHV (HHV8) serology in Europe and Uganda: A multicentric study with multiple and novel assays
- Author
-
Paolo Monini, Schatz, O., Bugarini, R., Neipel, F., Schulz, Tf, Andreoni, M., Erb, P., Eggers, M., Haas, J., Butto, S., Lukwiya, M., Bogner, Jr, Yaguboglu, S., Sheldon, J., Nicastri, E., Goebel, Fd, Hintermaier, R., Enders, G., Regamay, N., Wernli, M., Sturzl, M., Rezza, G., and Ensoli, B.
29. Verwendung der Muskelsaugbiopsienadel für bioptische Diagnostik
- Author
-
Hoffmann G and Goebel Fd
- Subjects
medicine.medical_specialty ,medicine.anatomical_structure ,business.industry ,Aspiration biopsy ,medicine ,Skeletal muscle ,General Medicine ,Radiology ,business - Abstract
The needle for aspiration biopsy of skeletal muscle, previously developed for biochemical and physiological purposes, has been introduced in the diagnosis of muscular and vascular diseases. Evidence is presented that this needle is a useful tool for routine evaluation of such disorders.
- Published
- 1976
- Full Text
- View/download PDF
30. What's new in HIV/AIDS: can science solve the global AIDS problem?
- Author
-
Goebel FD
- Abstract
Recently, the 15th International AIDS Conference took place in Bangkok, Thailand. This conference used to be an almost exclusively science-oriented conference reporting on new developments in diagnostic tools, drug discovery, and other medical advances, making it a 'must attend' event for most scientists. In the year 2000, this congress was hosted by South Africa in Durban, for the first time in a developing country - focusing on the particular needs of poor countries and also stressing that scientific approaches are not the only relevant and important aspects of this global epidemic. While many scientist (including this author) perceived the changing emphasis of the meeting with regret ('only science will solve this problem'), the immediate view on the epidemic in areas with poor resources has proven beyond doubt that HIV is far more than just a viral infection. With the latest conference taking place in Bangkok, several particular aspects were demonstrated: after Africa, Asia is the largest hot spot in the worldwide spread of HIV with the highest increase in infections. Also, this country can serve as an admirable example of political will and successful battle to constrain the epidemic despite a serious lack of resources. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
31. Nef-specific CD45RA+ CD8+ T cells secreting MIP-1ß but not IFN-gamma are associated with nonprogressive HIV-1 infection.
- Author
-
Dembek CJ, Kutscher S, Heltai S, Allgayer S, Biswas P, Ghezzi S, Vicenzi E, Hoffmann D, Reitmeir P, Tambussi G, Bogner JR, Lusso P, Stellbrink H, Santagostino E, Vollbrecht T, Goebel FD, Protzer U, Draenert R, Tinelli M, and Poli G
- Published
- 2010
- Full Text
- View/download PDF
32. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes
- Author
-
Ledergerber, B, Lundgren, Jd, Walker, As, Sabin, C, Justice, A, Reiss, P, Mussini, C, Wit, F, d'Arminio Monforte, A, Weber, R, Fusco, G, Staszewski, S, Law, M, Hogg, R, Lampe, F, Gill, Mj, Castelli, Francesco, Phillips, An, Rooney, P. q, Taylor, S. q, Couldwell, D. r, Austin, D. s, Block, M. s, Clemons, J. s, Finlayson, R. s, Petoumenos, K. s, Quan, D. s, Smith, D. s, O'Connor, C. t, Gorton, C. t, Allen, D. u, Mulhall, B. u, Mutimer, K. v, Keeffe, N. v, Cooper, D. w, Carr, A. w, Miller, J. w, Pell, C. w, Ellis, D. x, Baker, D. y, Kidd, J. y, Mcfarlane, R. y, Liang, M. T. z, Brown, Aa, K., Huffam, Ab, S., Savage, Ab, J., Morgan, Knibbs, Ab, P., Sowden, Ac, D., Walker, Ac, A., Orth, Ad, D., Lister, Ad, G., Chuah, Ae, J., Fankhauser, Ae, W., Dickson, Ae, B., Bradford, Af, D., Wilson, Af, C., Ree, Ag, H., Magon, Anderson, Ah, J., Moore, Ah, R., Russell, Ah, D., Mcgovern, Ah, G., Mcnair, Bal, Fairley, Ah, K., Roth, Ai, N., Ai, B., Strecker, Ai, S., Ai, D., Wood, Ai, H., Mijch, Aj, A., Hoy, Aj, J., Pierce, Mccormack, Aj, C., Watson, Aj, K., Medland, Ak, N., Daye, Al, J., Mallal, Am, S., French, Am, M., Skett, Am, J., Maxwel, Am, D., Cain, Am, A., Montroni, An, M., Scalise, An, G., Costantini, An, A., Giacometti, Tirelli, Ao, U., Nasti, Ao, G., Pastore, Ap, G., Ladisa, Ap, N., Perulli, M. L., Ap, Suter, Aq, F., Arici, Aq, C., Maggiolo, Chiodo, Ar, F., Gritti, F. M., Ar, Colangeli, Ar, V., Fiorini, Ar, C., Guerra, Ar, L., Carosi, As, G., Cadeo, G. P., As, Minardi, As, C., Vangi, As, D., Paraninfo, Casari, As, S., Pan, As, A., Patroni, Torti, Quiros, Roldan, As, E., Tomasoni, As, L., Moretti, As, F., Nasta, As, P., Uccelli, M. C., As, Bertelli, Rizzardini, At, G., Migliorino, At, M., Abeli, At, C., Manconi, P. E., Au, Piano, Au, P., Ferraro, Av, T., Scerbo, Av, A., Pizzigallo, Aw, E., Ricci, Aw, F., Santoro, Ax, D., Pusterla, Ax, L., Carnevale, Ay, G., Galloni, Ay, D., Viganò, Az, P., Mena, Az, M., Ghinelli, Ba, F., Sighinolfi, Ba, L., Leoncini, Bb, F., Mazzotta, Pozzi, Bb, M., Caputo, Lo, Bb, S., Angarano, Bc, G., Grisorio, Bc, B., Ferrara, Bc, S., Grima, Bd, P., Tundo, Pagano, Be, G., Piersantelli, Be, N., Alessandrini, Be, A., Piscopo, Be, R., Toti, Bf, M., Chigiotti, Bf, S., Soscia, Bg, F., Tacconi, Bg, L., Orani, Bh, A., Perini, Bh, P., Nigro, Bh, M., Scasso, Bi, A., Vincenti, Scalzini, Bj, A., Fibbia, Bj, G., Moroni, Bk, M., Lazzarin, Bk, A., Cargnel, Vigevani, G. M., Bk, Caggese, Bk, L., Tordato, Bk, F., Novati, Bk, R., Galli, Merli, Bk, S., Pastecchia, Bk, C., Moioli, Esposito, Bl, R., Abrescia, Bm, N., Chirianni, Bm, A., Izzo, Bm, C., Piazza, Bm, M., Marco, De, Montesarchio, Bm, V., Manzillo, Bm, E., Nappa, Bm, S., Colomba, Bn, A., Abbadessa, Bn, V., Prestileo, Bn, T., Mancuso, Bn, S., Ferrari, Bo, C., Pzzaferri, Bo, P., Filice, Bp, G., Minoli, Bp, L., Bruno, Bp, R., Maserati, Bp, S., Tinelli, Bp, C., Pauluzzi, Bq, S., Baldelli, Bq, F., Petrelli, Br, E., Cioppi, Br, A., Alberici, Bs, F., Ruggieri, Bs, A., Menichetti, Bt, F., Martinelli, Bt, C., Stefano, De, Bu, C., Gala, La, Bu, A., Zauli, Bv, T., Ballardini, Bv, G., Magnani, Bw, G., Ursitti, M. A., Bw, Arlotti, Bx, M., Ortolani, Bx, P., Ortona, By, L., Dianzani, By, F., Ippolito, By, G., Antinori, Bz, A., Antonucci, Bz, G., D'Elia, Bz, S., Narciso, Bz, P., Petrosillo, Bz, N., Vullo, Bz, V., Luca, De, Del, Forno, Bz, L., Zaccarelli, Bz, M., Longis, De, Ciardi, D'Offizi, Noto, Lichtner, Capobianchi, M. R., Bz, Girardi, Bz, E., Pezzotti, Rezza, Mura, M. S., Ca, Mannazzu, Ca, M., Caramello, Cb, P., Sinicco, Cb, A., Soranzo, M. L., Cb, Gennero, Cb, L., Sciandra, Cb, M., Salassa, Cb, B., Grossi, P. A., Cc, Basilico, Cc, C., Poggio, Cd, A., Bottari, Cd, G., Raise, Ce, E., Pasquinucci, Ce, S., Lalla, De, Cf, F., Tositti, Cf, G., Resta, Cg, F., Chimienti, Cg, A., Lepri, Cozzi, Ch, A., Bachmann, Fb, S., Battegay, Fb, M., Bernasconi, Fb, E., Bucher, Fb, H., Bürgisser, Fb, P., Cattacin, Egger, Erb, Fierz, Fb, W., Fischer, Flepp, Fontana, Fb, A., Francioli, Furrer, H. J., Fb, Gorgievski, Günthard, Hirschel, Fb, B., Kaiser, Fb, L., Kind, Fb, C., Klimkait, Fb, T., Lauper, Fb, U., Opravil, Paccaud, Fb, F., Pantaleo, Fb, G., Perrin, Piffaretti, J. C., Fb, Rickenbach, Rudin, Schüpbach, Fb, J., Speck, Fb, R., Tarr, Telenti, Trkola, Vernazza, Yerly, Wolf, De, Ci, F., Van, Sighem, A. I., Ci, Van, Valkengoed, Ci, I., Gras, Ci, L., Bronsveld, Ci, W., Veldkamp, Ci, A., Prins, J. M., Cj, Bos, J. C., Cj, Schattenkerk, Eeftinck, J. K. M., Cj, Godfried, M. H., Cj, Lange, J. M. A., Cj, Lowe, S. H., Cj, van der Meer, J. T. M., Cj, Nellen, F. J. B., Cj, Pogany, Cj, K., van der Poll, Cj, T., Ruys, T. A., Cj, Sankatsing, Cj, S., van der Valk, Cj, M., Van, Vonderen, M. G. A., Cj, Wit, F. W. M. N., Cj, Van, Eeden, Cj, A., Ten, Veen, J. H., Cj, Van, Dam, P. S., Cj, Hillebrand, Haverkort, M. E., Cj, Brinkman, Frissen, P. H. J., Cj, Weigel, H. M., Cj, Mulder, J. W., Cj, Van, Gorp, E. C. M., Cj, Meenhorst, P. L., Cj, Mairuhu, A. T. A., Cj, Veenstra, Cj, J., Danner, S. A., Cj, Van, Agtmael, M. A., Cj, Claessen, F. A. P., Cj, Geerlings, S. E., Cj, Perenboom, R. M., Cj, Jurriaans, Back, N. K. T., Cj, Cuijpers, Rietra, P. J. G. M., Cj, Roozendaal, K. J., Cj, Pauw, Cj, W., Van, Zanten, A. P., Cj, Smits, P. H. M., Cj, Von, Blomberg, B. M. E., Cj, Savelkoul, Cj, P., Zaaijer, Cj, H., Beijnen, Crommentuyn, K. M. L., Cj, Huitema, A. D. R., Cj, Kappelhoff, Cj, B., Maat, De, M. M. R., Cj, Richter, Ck, C., van der Berg, Ck, J., Van, Leusen, Ck, R., Swanink, Vriesendorp, Cl, R., Jeurissen, F. J. F., Cl, Kauffmann, R. H., Cm, Koger, E. L. W., Cm, Franck, P. F. H., Cm, Lampe, A. S., Cm, Jansen, C. L., Cm, Bravenboer, Cn, B., Ten, Napel, C. H. H., Co, Mudrikova, Co, T., Hendriks, Co, R., Sprenger, H. G., Cp, Miesen, W. M. A. J., Cp, Schirm, Cp, J., Benne, Cp, D., Ten, Kate, R. W., Cq, Veenendaal, Cq, D., Van, Houte, D. P. F., Cr, Leemhuis, M. P., Cr, Pole, Cr, M., Storm, Cr, H., Van, Zeijl, J. H., Cr, Kroon, F. P., Cs, Schippers, E. F., Cs, Kroes, A. C. M., Cs, Claas, H. C. J., Cs, Schreij, Ct, G., van de Geest, Ct, S., Verbon, Ct, A., Bruggeman, C. A. M. V. A., Ct, Goossens, V. J., Ct, Koopmans, P. P., Cu, Telgt, Cu, M., van der Ven, A. J. A. M., Cu, Burger, D. M., Cu, Hugen, P. W. H., Cu, Galama, J. M. D., Cu, Poort, Y. A. G. M., Cu, van der Ende, M. E., Cv, Gyssens, I. C., Cv, Marie, De, Cv, S., Nouwen, J. L., Cv, Niesters, M. G., Cv, Osterhaus, A. D. M. E., Cv, Schutten, Cv, M., Juttmann, J. R., Cw, Buiting, A. G. M., Cw, Swaans, C. A. M., Cw, Schneider, M. M. E., Cx, Bonten, M. J. M., Cx, Borleffs, J. C. C., Cx, Hoepelman, I. M., Cx, Jaspers, C. A. J. J., Cx, Schouten, Cx, I., Schurink, C. A. M., Cx, Boucher, C. A. B., Cx, Schuurman, Cx, R., Blok, W. L., Cy, Groeneveld, P. H. P., Cz, Boel, Da, E., Jansz, A. F., Da, Dabis, Db, F., Thiebaut, Db, R., Chêne, Db, G., Lawson, Ayayi, Db, S., Meyer, Dc, L., Boufassa, Dc, F., Hamouda, Dd, O., De, P., De, G., Touloumi, Df, G., Hatzakis, Df, A., Karafoulidou, Katsarou, Df, O., Brettle, Dg, R., Del, Amo, Dh, J., Del, Romero, Van, Asten, Di, L., Van, Benthem, Di, B., Di, M., Coutinho, Di, R., Kirk, Dj, O., Pedersen, Dj, C., Hernández, Aguado, Dk, I., Pérez, Hoyos, Dk, S., Eskild, Dl, A., Bruun, J. N., Dl, Sannes, Dl, M., Lee, Dm, C., Johnson, A. M., Dn, Babiker, Dn, A., Darbyshire, Dn, J., Gill, Dn, N., Porter, Dn, K., Do, P., Vanhems, Do, M., Cooper, Dp, D., Kaldor, Dpdq, J., Ashton, Dp, L., Dq, D., Dq, L., Vizzard, Dq, J., Muga, Dr, R., Ds, P., Dt, J., Cayla, Du, J., Garcia de Olalla, Du, P., Day, N. E., Dv, Angelis, De, Dv, D., Fb, K., Dw, A., Dw, S., Dw, J., Tyrer, Dw, F., Beral, Fb, V., Fb, N., Raffanti, Becker, Scarsella, Braun, Most, Balu, Gilbert, Fleenor, Ising, Dieterich, Fb, D., Fusco, Losso, Dx, M., Duran, Dx, A., Vetter, Dy, N., Clumeck, Dz, N., Wit, De, Dz, S., Kabeya, Dz, K., Poll, Dz, B., Colebunders, Dz, R., Machala, Ea, L., Rozsypal, Ea, H., Nielsen, Eb, J., Lundgren, Eb, O., Olsen, C. H., Eb, Gerstoft, Katzenstein, Eb, T., Hansen, A. B. E., Eb, Skinhøj, Eb, P., Eb, C., Zilmer, Ec, K., Rauka, Ec, M., Katlama, Ed, C., De, Sa, Ed, M., Viard, J. P., Ed, Saint, Marc, Ed, T., Ed, P., Pradier, Dietrich, Ee, M., Manegold, Ee, C., Van, Lunzen, Ee, J., Stellbrink, H. J., Ee, Miller, Ee, V., Goebel, F. D., Ee, Salzberger, Ee, B., Rockstroh, Kosmidis, Ef, J., Gargalianos, Ef, P., Sambatakou, Ef, H., Perdios, Panos, Ef, G., Filandras, Ef, A., Banhegyi, Eg, D., Mulcahy, Eh, F., Yust, Ei, I., Burke, Ei, M., Pollack, Ei, S., Hassoun, Ei, J., Sthoeger, Ei, Z., Maayan, Vella, Ej, S., Chiesi, Ej, A., Ej, C., Pristerá, Ej, R., Ej, F., Gabbuti, Bedini, Ej, E., Ej, V., Santopadre, Ej, P., Franci, Ej, M., Castagna, Viksna, Ek, L., Rozentale, Ek, B., Chaplinskas, El, S., Hemmer, Em, R., Staub, Em, T., En, J., Maeland, En, A., Ormaasen, En, V., Knysz, Eo, B., Gasiorowski, Eo, J., Horban, Eo, A., Prokopowicz, Eo, D., Wiercinska, Drapalo, Boron, Kaczmarska, Pynka, Eo, M., Beniowski, Trocha, Eo, H., Smiatacz, Eo, T., Antunes, Ep, F., Mansinho, Ep, K., Maltez, Duiculescu, Eq, D., Streinu, Cercel, Eq, A., Mokrás, Er, M., Staneková, Er, D., González, Lahoz, Es, J., Diaz, Es, B., García, Benayas, Es, T., Martin, Carbonero, Es, L., Soriano, Es, V., Clotet, Jou, Es, A., Conejero, Tural, Es, C., Gatell, J. M., Es, Miró, Zamora, Blaxhult, Et, A., Karlsson, Pehrson, Et, P., Eu, P., Eu, B., Schiffer, Eu, V., Eu, H., Chentsova, Ev, N., Barton, Ew, S., A. M., Ew, Mercey, Ew, D., Phillips, Ew, A., Youle, Ew, M., M. A., Ew, Mocroft, Murphy, Weber, Ew, J., Scullard, Ew, G., Fisher, Ew, R., Loveday, Ew, C., Ex, B., Ruiz, Ex, L., Helm, E. B., Fb, Carlebach, Mösch, Müller, Haberl, Korn, Stephan, Bickel, Gute, Locher, Lutz, Klauke, Doerr, H. W., Fb, Stürmer, Dauer, Jennings, Alexander, Braitstein, Chan, Cote, Gataric, Harrigan, P. R., Fb, Harris, Bonner, Montaner, O'Shaughnessy, Yip, Chaloner, Gumley, Ransom, Sabin, C. A., Fb, Lipman, Ey, J., Read, Ey, R., Ez, F., Riccio, Fa, G., Borghi, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Infectious diseases, Global Health, Other departments, Public and occupational health, General Internal Medicine, Center of Experimental and Molecular Medicine, Ledergerber, B, Lundgren, Jd, Walker, A, Sabin, C, Justice, A, Reiss, P, Mussini, C, Wit, F, Monforte, Ad, Weber, R, Fusco, G, Staszewski, S, Law, M, Hogg, R, Lampe, F, Gill, Mj, Castelli, F, Phillips, An, Fusco, Gp, Rooney, P, Taylor, S, Couldwell, D, Austin, D, Block, M, Clemons, J, Finlayson, R, Petoumenos, K, Quan, D, Smith, D, O'Connor, C, Gorton, C, Allen, D, Mulhall, B, Mutimer, K, Keeffe, N, Cooper, D, Carr, A, Miller, J, Pell, C, Ellis, D, Baker, D, Kidd, J, Mcfarlane, R, Liang, Mt, Brown, K, Huffam, S, Savage, J, Morgan, S, Knibbs, P, Sowden, D, Orth, D, Lister, G, Chuah, J, Fankhauser, W, Dickson, B, Bradford, D, Wilson, C, Ree, H, Magon, H, Anderson, J, Moore, R, Russell, D, Mcgovern, G, Mcnair, R, Bal, J, Fairley, K, Roth, N, Eu, B, Strecker, S, Wood, H, Mijch, A, Hoy, J, Pierce, A, Mccormack, C, Watson, K, Medland, N, Daye, J, Mallal, S, French, M, Skett, J, Maxwel, D, Cain, A, Montroni, M, Scalise, G, Costantini, A, Giacometti, A, Tirelli, U, Nasti, G, Pastore, G, Ladisa, N, Perulli, Ml, Suter, F, Arici, C, Chiodo, F, Gritti, Fm, Colangeli, V, Fiorini, C, Guerra, L, Carosi, G, Cadeo, Gp, Minardi, C, Vangi, D, Rizzardini, G, Migliorino, G, Manconi, Pe, Piano, P, Ferraro, T, Scerbo, A, Pizzigallo, E, Ricci, F, Santoro, D, Pusterla, L, Carnevale, G, Galloni, D, Vigano, P, Mena, M, Ghinelli, F, Sighinolfi, L, Leoncini, F, Mazzotta, F, Pozzi, M, Lo Caputo, S, Angarano, G, Grisorio, B, Ferrara, S, Grima, P, Tundo, P, Pagano, G, Piersantelli, N, Alessandrini, A, Piscopo, R, Toti, M, Chigiotti, S, Soscia, F, Taccooni, L, Orani, A, Perini, P, Scasso, A, Vincenti, A, Scalzini, A, Fibbia, G, Moroni, M, Lazzarin, A, Cargnel, A, Vigevani, Gm, Caggese, L, Tordato, F, Novati, R, Galli, A, Merli, S, Pastecchia, C, Moioli, C, Esposito, R, Abrescia, N, Chirianni, A, Izzo, C, Piazza, M, De Marco, M, Montesarchio, V, Manzillo, E, Nappa, S, Colomba, A, Abbadessa, V, Prestileo, T, Mancuso, S, Ferrari, C, Pzzaferri, P, Filice, G, Minoli, L, Bruno, R, Maserati, R, Pauluzzi, S, Baldelli, F, Petrelli, E, Cioppi, A, Alberici, F, Ruggieri, A, Menichetti, F, Martinelli, C, De Stefano, C, La Gala, A, Zauli, T, Ballardini, G, Magnani, G, Ursitti, Ma, Arlotti, M, Ortolani, P, Ortona, L, Dianzani, F, Ippolito, G, Antinori, A, Antonucci, G, D'Elia, S, Narciso, P, Petrosillo, N, Vullo, V, De Luca, A, Del Forno, L, Zaccarelli, M, De Longis, P, Ciardi, M, D'Offizi, G, Noto, P, Lichtner, M, Capobianchi, Mr, Girardi, E, Pezzotti, P, Rezza, G, Mura, M, Mannazzu, M, Caramello, P, Sinicco, A, Soranzo, Ml, Gennero, L, Sciandra, M, Salassa, B, Grossi, Pa, Basilico, C, Poggio, A, Bottari, G, Raise, E, Pasquinucci, S, De Lalla, F, Tositti, G, Resta, F, Chimienti, A, Lepri, Ac, Bachmann, S, Battegay, M, Bernasconi, E, Bucher, H, Burgisser, P, Cattacin, S, Egger, M, Erb, P, Fierz, W, Fischer, M, Flepp, M, Fontana, A, Francioli, P, Furrer, Hj, Gorgievski, M, Hirschel, B, Kaiser, L, Kind, C, Klimkait, T, Lauper, U, Opravil, M, Paccaud, F, Pantaleo, G, Perrin, L, Piffaretti, Jc, Rickenbach, M, Rudin, C, Schupbach, J, Speck, R, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Yerly, S, de Wolf, F, van Sighem, Ai, van Valkengoed, I, Gras, L, Bronsveld, W, Prins, Jm, Bos, Jc, Schattenkerk, Jkme, Godfried, Mh, Lange, Jma, Lowe, Sh, van der Meer, Jtm, Nellen, Fjb, Pogany, K, van der Poll, T, Ruys, Ta, Sankatsing, S, van der Valk, M, van Vonderen, Mga, Wit, Fwmn, van Eeden, A, ten Veen, Jh, van Dam, P, Hillebrand Haverkort, Me, Brinkman, K, Frissen, Phj, Weigel, Hm, Mulder, Jw, van Gorp, Ecm, Meenhorst, Pl, Mairuhu, Ata, Veenstra, J, Danner, Sa, Van Agtmael, Ma, Claessen, Fap, Geerlings, Se, Perenboom, Rm, Richter, C, van der Berg, J, van Leusen, R, Vriesendorp, R, Jeurissen, Fjf, Kauffmann, Rh, Koger, Elw, Bravenboer, B, ten Napel, Chh, Mudrikova, T, Sprenger, Hg, Miesen, Wmaj, ten Kate, Rw, van Houte, Dpf, Leemhuis, Mp, Pole, M, Kroon, Fp, Schippers, Ef, Schreij, G, van de Geest, S, Verbon, A, Koopmans, Pp, Telgt, M, van der Ven, Ajam, van der Ende, Me, Gyssens, Ic, de Marie, S, Nouwen, Jl, Juttmann, Jr, Schneider, Mme, Bonten, Mjm, Borleffs, Jcc, Hoepelman, Im, Jaspers, Cajj, Schouten, I, Schurink, Cam, Blok, Wl, Groenveld, Php, Jurriaans, S, Back, Nkt, Cuijpers, T, Rietra, Pjgm, Roozendaal, Kj, Pauw, W, van Zanten, Ap, Smits, Phm, von Blomberg, Bme, Savelkoul, P, Zaaijer, H, Swanink, C, Franck, Pfh, Lampe, A, Jansen, Cl, Hendriks, R, Schirm, J, Benne, D, Veenendaal, D, Storm, H, van Zeijl, Jh, Kroes, Acm, Claas, Hcj, Bruggeman, Camva, Goossens, Vj, Galama, Jmd, Poort, Yagm, Niesters, Mg, Osterhaus, Adme, Schutten, M, Buiting, Agm, Swaans, Cam, Boucher, Cab, Schuurman, R, Boel, E, Jansz, Af, Veldkamp, A, Beijnen, Jh, Crommentuyn, Kml, Huitema, Adr, Kappelhoff, B, de Maat, Mmr, Burger, Dm, Hugen, Pwh, Dabis, F, Thiebaut, R, Chene, G, Lawson Ayayi, S, Meyer, L, Boufassa, F, Hamouda, O, Touloumi, G, Hatzakis, A, Karafoulidou, A, Katsarou, O, Brettle, R, Del Amo, J, del Romero, J, van Asten, L, van Benthem, B, Prins, M, Coutinho, R, Kirk, O, Pedersen, C, Aguado, Ih, Perez Hoyos, S, Eskild, A, Bruun, Jn, Sannes, M, Lee, C, Johnson, Am, Babiker, A, Darbyshire, J, Gill, N, Porter, K, Vanhems, P, Kaldor, J, Ashton, L, Vizzard, J, Muga, R, Gill, J, Cayla, J, de Olalla, Pg, Day, Ne, De Angelis, D, Walker, S, Tyrer, F, Beral, V, Raffanti, S, Becker, S, Scarsella, A, Braun, J, Most, B, Balu, R, Gilbert, L, Fleenor, R, Ising, T, Dieterich, D, Fusco, J, Losso, M, Duran, A, Vetter, N, Clumeck, N, De Wit, S, Kabeya, K, Poll, B, Colebunders, R, Machala, L, Rozsypal, H, Nielsen, J, Lundgren, J, Olsen, Ch, Gerstoft, J, Katzenstein, T, Hansen, Abe, Skinhoj, P, Zilmer, K, Rauka, M, Katlama, C, De Sa, M, Viard, Jp, Saint Marc, T, Pradier, C, Dietrich, M, Manegold, C, van Lunzen, J, Stellbrink, Hj, Miller, V, Goebel, Fd, Salzberger, B, Rockstroh, J, Kosmidis, J, Gargalianos, P, Sambatakou, H, Perdios, J, Panos, G, Filandras, A, Banhegyi, D, Mulcahy, F, Yust, I, Burke, M, Pollack, S, Hassoun, J, Sthoeger, Z, Maayan, S, Vella, S, Chiesi, A, Pristera, R, Gabbuti, A, Bedini, A, Montesarchio, E, Santopadre, P, Franci, P, Castagna, Antonella, Viksna, L, Rozentale, B, Chaplinskas, S, Hemmer, R, Staub, T, Bruun, J, Maeland, A, Ormaasen, V, Knysz, B, Gasiorowski, J, Horban, A, Prokopowicz, D, Wiercinska Drapalo, A, Boron Kaczmarska, A, Pynka, M, Beniowski, M, Trocha, H, Smiatacz, T, Antunes, F, Mansinho, K, Maltez, F, Duiculescu, D, Streinu Cercel, A, Mokras, M, Stanekova, D, Gonzalez Lahoz, J, Diaz, B, Garcia Benayas, T, Martin Carbonero, L, Soriano, V, Clotet, B, Jou, A, Conejero, J, Tural, C, Gatell, Jm, Miro, Jm, Zamora, L, Blaxhult, A, Karlsson, A, Pehrson, P, Schiffer, V, Furrer, H, Chentsova, N, Barton, S, Mercey, D, Phillips, A, Youle, M, Johnson, Ma, Mocroft, A, Murphy, M, Weber, J, Scullard, G, Fisher, M, Loveday, C, Ruiz, L, Helm, Eb, Carlebach, A, Mosch, M, Muller, A, Haberl, A, Korn, S, Stephan, C, Bickel, M, Gute, P, Locher, L, Lutz, T, Klauke, S, Doerr, Hw, Sturmer, M, Dauer, B, Jennings, B, Alexander, C, Braitstein, P, Chan, K, Cote, H, Gataric, N, Harrigan, Pr, Harris, M, Bonner, S, Montaner, J, O'Shaughnessy, M, Wood, E, Yip, B, Chaloner, C, Gumley, H, Ransom, D, Sabin, Ca, Lipman, M, Johnson, M, Read, R, Paraninfo, G, Casari, S, Pan, A, Patroni, A, Torti, C, Quiros Roldan, E, Tomasoni, L, Moretti, F, Nasta, P, Uccelli, Mc, Bertelli, D, Nigro, M, Migliorino, M, Abeli, C, Maggiolo, F, Novati, S, Tinelli, C, Riccio, G, Borghi, V, and Esposito, R.
- Subjects
Male ,HAART ,Human immunodeficiency virus (HIV) ,CD4 cell count ,HIV Infections ,CLINICAL PROGRESSION ,medicine.disease_cause ,THERAPY ,HAART REGIMEN ,Cohort Studies ,Risk Factors ,Adult, Anti-Retroviral Agents, CD4 Lymphocyte Count, Cohort Studies, Female, Follow-Up Studies, HIV Infections, HIV Protease Inhibitors, HIV-1, Humans, Male, Middle Aged, Proportional Hazards Models, Reverse Transcriptase Inhibitors, Risk Factors, Treatment Failure, Viral Load ,Medicine ,Treatment Failure ,Mortality rate ,Medicine (all) ,INHIBITOR ,General Medicine ,Middle Aged ,HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) ,BLIND CONTROLLED-TRIAL ,medicine.anatomical_structure ,Anti-Retroviral Agents ,Cohort ,HUMAN-IMMUNODEFICIENCY-VIRUS ,Reverse Transcriptase Inhibitors ,Female ,Off Treatment ,Viral load ,Cohort study ,Adult ,medicine.medical_specialty ,Settore MED/17 - Malattie Infettive ,T cell ,Internal medicine ,Humans ,COHORT ,Proportional Hazards Models ,business.industry ,Proportional hazards model ,DISEASE PROGRESSION ,HIV Protease Inhibitors ,HIV-INFECTED INDIVIDUALS ,CD4 Lymphocyte Count ,VIRAL LOAD ,Immunology ,HIV-1 ,business ,Follow-Up Studies - Abstract
Background Treatment strategies for patients in whom HIV replication is not suppressed after exposure to several drug classes remain unclear. We aimed to assess the inter-relations between viral load, CD4-cell count, and clinical outcome in patients who had experienced three-class virological failure.Methods We undertook collaborative joint analysis of 13 HIV cohorts from Europe, North America, and Australia, involving patients who had had three-class virological failure (viral load >1000 copies per mL for >4 months). Regression analyses were used to quantify the associations between CD4-cell-count slope, HIV-1 RNA concentration, treatment information, and demographic characteristics. Predictors of death were analysed by Cox's proportional-hazards models.Findings 2488 patients were included. 2118 (85%) had started antiretroviral therapy with single or dual therapy. During 5015 person-years of follow-up, 276 patients died (mortality rate 5.5 per 100 person-years; 3-year mortality risk 15.3% (95% Cl 13.5-17.3). Risk of death was strongly influenced by the latest CD4-cell count with a relative hazard of 15.8 (95% CI 9.28-27.0) for counts below 50 cells per muL versus above 200 cells per muL. The latest viral load did not independently predict death. For any given viral load, patients on treatment had more favourable CD4-cell-count slopes than those off treatment. For patients on treatment and with stable viral load, CD4-cell counts tended to be increasing at times when the current viral load was below 10 000 copies per mL or 1.5 log(10) copies per mL below off-treatment values.Interpretation In patients for whom viral-load suppression to below the level of detection is not possible, achievement and maintenance of a CD4-cell count above 200 per muL becomes the primary aim. Treatment regimens that maintain the viral load below 10 000 copies per mL or at least provide 1.5 log(10) copies per mL suppression below the off-treatment value do not seem to be associated with appreciable CD4-cell-count decline.
- Published
- 2004
33. Macro CK2 accumulation in tenofovir-treated HIV patients is facilitated by CK oligomer stabilization but is not predictive for pathology.
- Author
-
Schmid H, Tokarska-Schlattner M, Füeßl B, Röder M, Kay L, Attia S, Lederer SR, Goebel FD, Schlattner U, and Bogner JR
- Subjects
- Adenine pharmacology, Adenine therapeutic use, Anti-HIV Agents therapeutic use, Catalysis drug effects, Creatine Kinase, Mitochondrial Form blood, Creatine Kinase, Mitochondrial Form chemistry, Enzyme Stability, Follow-Up Studies, Glomerular Filtration Rate drug effects, HIV Infections blood, HIV Infections drug therapy, Humans, Hypophosphatemia blood, Organophosphonates therapeutic use, Tenofovir, Adenine analogs & derivatives, Anti-HIV Agents pharmacology, Creatine Kinase, Mitochondrial Form metabolism, HIV Infections metabolism, Organophosphonates pharmacology, Protein Multimerization drug effects
- Abstract
Background: Ubiquitous mitochondrial creatine kinase (uMtCK) accumulates as macroenzyme creatine kinase type 2 (macro CK2) in the serum of HIV-infected patients under a tenofovir disoproxil fumarate (TDF)-containing antiretroviral regimen. The genesis and clinical significance of this finding is unclear., Methods: A prospective observational 5-year follow-up study was performed on those patients in which macro CK2 appearance was initially described ('TDF switch study' cohort). In addition, tenofovir (TFV), its prodrug TDF and its active, intracellular derivative TFV diphosphate (TDP) were tested in vitro for their effects on different key properties of uMtCK to clarify possible interactions of uMtCK with TFV compounds., Results: In just under 5 years of continuous TDF treatment, only 4/12 (33%) patients remained macro CK2-positive, whereas 8/12 (66%) originally positive patients were macro CK2-negative at the end of follow-up. Prospective clinical follow-up data indicate that macro CK2 appearance under TDF is not associated with significant cell damage or occurrence of malignancies. A trend towards grade 1 hypophosphataemia suggests subclinical proximal tubular dysfunction in macro-CK2-positive patients, although it was not associated with a significant decrease in estimated glomerular filtration rate. In vitro, TFV, TDF and TDP did not interfere with uMtCK enzyme activity as competitive inhibitors or pseudo-substrates, but TFV and TDF stabilized the native uMtCK octameric structure in dilute solutions., Conclusions: Appearance of octameric uMtCK as macro CK2 in the serum of TDF-treated patients is suggested to result from a combination of low-level mitochondrial damage caused by subclinical renal tubular dysfunction together with possible compensatory uMtCK overexpression and a putative concomitant stabilization of uMtCK octamers by higher levels of TFV in proximal tubules.
- Published
- 2013
- Full Text
- View/download PDF
34. Longitudinal changes in HIV-1-specific T-cell quality associated with viral load dynamic.
- Author
-
Dembek CJ, Kutscher S, Allgayer S, Russo C, Bauer T, Hoffmann D, Goebel FD, Bogner JR, Erfle V, Protzer U, and Cosma A
- Subjects
- Anti-HIV Agents administration & dosage, Biomarkers, CD40 Ligand metabolism, Chemokine CCL4 metabolism, HIV Infections drug therapy, HIV-1 immunology, Humans, Interferon-gamma metabolism, Interleukin-2 metabolism, Leukocyte Common Antigens metabolism, Longitudinal Studies, Prognosis, Withholding Treatment, HIV Infections immunology, HIV Infections virology, HIV-1 isolation & purification, T-Lymphocytes immunology, Viral Load
- Abstract
Background: Several correlates of HIV control have been described; however their predictive values remain unclear, since most studies have been performed in cross-sectional settings., Objectives: We evaluated the cause and consequence relationship between quality of HIV-specific T-cell response and viral load dynamic in a temporal perspective., Study Design: HIV-1-specific T-cell responses were monitored over 7 years in a patient that following treatment interruption maintained a stable/low viral set point for 3.1 years before control of viral replication was lost and antiretroviral therapy restarted., Results: We observed that high frequencies of HIV-1-specific CD4 and CD8 T cells were unable to prevent loss of viral control. Gradual loss of functionality was observed in these responses, characterized by early loss of IL-2, viral load-dependent decrease of IFN-γ and CD154 expression as well as increase of MIP-1β production. Terminally differentiated HIV-1-specific CD8 T cells expressing CD45RA were lost independently of viral load and preceded the loss-of-control phase of HIV infection., Conclusion: By describing qualitative changes in HIV-1-specific T-cell responses that coincide with loss of viral control, we identified specific correlates of disease progression and putative markers of viral control. Our findings suggest including the markers IL-2, IFN-γ, MIP-1β, CD154 and CD45RA into monitoring of HIV-specific T-cell-responses to prospectively determine correlates of protection from disease-progression., (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
35. [Osteoporosis, vitamin D deficiency and renale failure].
- Author
-
Goebel FD
- Subjects
- Anti-HIV Agents adverse effects, Anti-HIV Agents therapeutic use, Bone Density drug effects, Humans, Kidney Failure, Chronic prevention & control, Mass Screening, Osteoporosis prevention & control, Risk Factors, Vitamin D Deficiency prevention & control, HIV Infections complications, HIV Infections epidemiology, Kidney Failure, Chronic epidemiology, Kidney Failure, Chronic etiology, Osteoporosis epidemiology, Osteoporosis etiology, Vitamin D Deficiency epidemiology, Vitamin D Deficiency etiology
- Published
- 2012
- Full Text
- View/download PDF
36. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
- Author
-
Kutscher S, Allgayer S, Dembek CJ, Bogner JR, Protzer U, Goebel FD, Erfle V, and Cosma A
- Subjects
- Antiretroviral Therapy, Highly Active, Cell Proliferation, Genetic Vectors genetics, HIV-1 genetics, Humans, Immunoassay, Interferon-gamma metabolism, Lymphocyte Activation genetics, Lymphocyte Activation immunology, Vaccines, DNA immunology, Vaccinia virus genetics, nef Gene Products, Human Immunodeficiency Virus genetics, nef Gene Products, Human Immunodeficiency Virus immunology, AIDS Vaccines immunology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, HIV Infections immunology, HIV-1 immunology
- Abstract
Several vaccination trials are evaluating the modified vaccinia virus Ankara (MVA) as a delivery vector in various clinical settings. In this paper, we present the reevaluation of a therapeutic vaccination trial in human immunodeficiency virus (HIV)-1-infected individuals treated with highly active antiretroviral therapy using MVA-expressing HIV-1 nef. Immunogenicity of MVA-nef was assessed using multicolor flow cytometry. Vaccine-induced polyfunctionality and proliferative capacity, which are associated with nonprogressive HIV-1 infection, were detectable by combining two immune assays. By means of short-term polychromatic intracellular cytokine staining, we observed a significant increase in polyfunctional Nef-specific CD4 T cells expressing interferon-γ, interleukin (IL)-2 and CD154 after vaccination, whereas changes in the quality of CD8 T-cell response could not be observed. Only the additional use of a long-term polychromatic Carboxyfluorescein succinimidyl ester (CFSE)-based proliferation assay revealed vaccine-induced Nef-specific CD8, as well as CD4 T cells with proliferative capacity. The correlation between vaccine-induced IL-2 production by CD4 T cells and the increase in proliferating Nef-specific CD8 T cells suggests a causal link between these two functions. These results highlight the importance of combining sophisticated immunomonitoring tools to unravel concealed effects of immunological interventions and support the use of the poxvirus-derived MVA vector to stimulate highly functional HIV-1-specific T-cell responses. However, the clinical benefit of these functional T cells remains to be determined.
- Published
- 2010
- Full Text
- View/download PDF
37. Impact of changes in antigen level on CD38/PD-1 co-expression on HIV-specific CD8 T cells in chronic, untreated HIV-1 infection.
- Author
-
Vollbrecht T, Brackmann H, Henrich N, Roeling J, Seybold U, Bogner JR, Goebel FD, and Draenert R
- Subjects
- Animals, Antigens, Viral immunology, Humans, Programmed Cell Death 1 Receptor, Viral Load immunology, ADP-ribosyl Cyclase 1 biosynthesis, Antigens, CD biosynthesis, Apoptosis Regulatory Proteins biosynthesis, CD8-Positive T-Lymphocytes immunology, Gene Expression, HIV Infections immunology, HIV-1 immunology, Membrane Glycoproteins biosynthesis
- Abstract
Excessive immune activation is a hallmark of chronic uncontrolled HIV infection. During the past years, growing evidence suggests that immune inhibitory signals also play an important role in progressive disease. However, the relationship between positive and negative immune signals on HIV-specific CD8 T cells has not been studied in detail so far in chronic HIV-1 infection. In this study, the expression of markers of positive (CD38) and negative (PD-1) immune signals on virus-specific CD8 T cells in chronic, untreated HIV-1 infection was evaluated using intracellular cytokine staining. Viral escape mutations were assessed by autologous virus sequence analysis and subsequent peptide titration assays. Single-epitope CD8 T-cell responses toward Gag, Pol, and Nef were compared in 12 HIV-1 controllers (viral load <5,000 cp/ml) and 12 HIV-1 progressors (viral load >50,000 cp/ml) and a highly significant increase of CD38/PD-1 co-expression on virus-specific CD8 T cells in progressors was found (P < 0.0001). The level of CD38/PD-1 co-expression was independent of epitope specificity. Longitudinal follow-up revealed a clear drop in CD38/PD-1 co-expression on virus-specific CD8 T cells after the suppression of antigen following either viral escape mutation or the initiation of HAART (P = 0.004). Antigen persistence with a fluctuating viral load revealed stable levels of CD38/PD-1 co-expression whereas significant rises in viral load were accompanied or even preceded by substantial increases in CD38/PD-1 co-expression. The CD38/PD-1 phenotype clearly distinguishes HIV-specific CD8 T-cell responses between controllers and progressors. Whether it plays a causative role in disease progression remains debatable. J. Med. Virol. 82:358-370, 2010. (c) 2010 Wiley-Liss, Inc.
- Published
- 2010
- Full Text
- View/download PDF
38. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.
- Author
-
Goebel FD, MacGregor TR, Sabo JP, Castles M, Johnson PA, Legg D, and McCallister S
- Subjects
- Adult, Anti-HIV Agents administration & dosage, Antiretroviral Therapy, Highly Active methods, Area Under Curve, CD4 Lymphocyte Count, Female, HIV Infections immunology, HIV Infections virology, Humans, Male, Pyridines administration & dosage, Pyrones administration & dosage, Ritonavir administration & dosage, Sulfonamides, Viral Load drug effects, Anti-HIV Agents pharmacokinetics, HIV Infections drug therapy, HIV-1, Pyridines pharmacokinetics, Pyrones pharmacokinetics, Ritonavir pharmacokinetics
- Abstract
Purpose: This study characterized the pharmacokinetic effects, safety, and antiretroviral activity of three different doses of the nonpeptidic protease inhibitor tipranavir, in combination with ritonavir administered twice daily for 28 days, on a number of triple-combination regimens containing a nonnucleoside reverse transcriptase inhibitor (efavirenz or nevirapine) plus two nucleoside reverse transcriptase inhibitors (abacavir, didanosine, lamivudine, stavudine, and zidovudine) or a three nucleoside reverse transcriptase inhibitor combination (zidovudine, lamivudine, and abacavir)., Methods: The study enrolled 208 HIV-1-positive patients who had been on stable antiretroviral treatment for at least 12 weeks prior to study entry and had an HIV-1 RNA load of delta 20,000 copies/mL. The patients were randomized to receive one of three dose combinations of tipranavir and ritonavir (1250/100 mg, 750/100 mg, and 250/200 mg) in addition to their antiretroviral (ARV) regimen for the next 22 days. The effects of twice-daily tipranavir and ritonavir combinations on the steady-state pharmacokinetics of the antiretrovirals were assessed by comparing pharmacokinetic parameters at baseline and after 3 weeks of coadministration., Results: No clinically relevant changes were observed in the Cmin, Cmax, or AUC parameters for nevirapine, efavirenz, lamivudine, stavudine, or didanosine, when coadministered with tipranavir and ritonavir at the dose combinations studied. All three dose combinations of tipranavir and ritonavir decreased the systemic exposure of abacavir (by 35% to 44%) and zidovudine (by 31% to 42%). Consistent with previous tipranavir studies, gastrointestinal adverse events were those most frequently observed. These reactions tended to be mild, with the majority being of Grade 1, and only 8 being of Grade 3 or 4 in intensity. Virologic response improved from 40.4% of participants at baseline with <50 copies/mL to 67.6% at Day 28 of study following addition of tipranavir and ritonavir., Conclusions: Tipranavir coadministered with ritonavir has been demonstrated to be safe, effective, and pose little potential for clinically meaningful drug interactions when added to the highly active antiretroviral therapy regimens containing nevirapine, efavirenz, lamivudine, stavudine, or didanosine.
- Published
- 2010
- Full Text
- View/download PDF
39. The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.
- Author
-
Kutscher S, Dembek CJ, Allgayer S, Heltai S, Stadlbauer B, Biswas P, Nozza S, Tambussi G, Bogner JR, Stellbrink HJ, Goebel FD, Lusso P, Tinelli M, Poli G, Erfle V, Pohla H, Malnati M, and Cosma A
- Abstract
Background: T-cell mediated immunity likely plays an important role in controlling HIV-1 infection and progression to AIDS. Several candidate vaccines against HIV-1 aim at stimulating cellular immune responses, either alone or together with the induction of neutralizing antibodies, and assays able to measure CD8 and CD4 T-cell responses need to be implemented. At present, the IFN-gamma-based ELISPOT assay is considered the gold standard and it is broadly preferred as primary assay for detection of antigen-specific T-cell responses in vaccine trials. However, in spite of its high sensitivity, the measurement of the sole IFN-gamma production provides limited information on the quality of the immune response. On the other hand, the introduction of polychromatic flow-cytometry-based assays such as the intracellular cytokine staining (ICS) strongly improved the capacity to detect several markers on a single cell level., Results: The cumulative analysis of 275 samples from 31 different HIV-1 infected individuals using an ICS staining procedure optimized by our laboratories revealed that, following antigenic stimulation, IFN-gamma producing T-cells were also producing MIP-1beta whereas T-cells characterized by the sole production of IFN-gamma were rare. Since the analysis of the combination of two functions decreases the background and the measurement of the IFN-gamma+ MIP-1beta+ T-cells was equivalent to the measurement of the total IFN-gamma+ T-cells, we adopted the IFN-gamma+ MIP-1beta+ data analysis system to evaluate IFN-gamma-based, antigen-specific T-cell responses. Comparison of our ICS assay with ELISPOT assays performed in two different experienced laboratories demonstrated that the IFN-gamma+ MIP-1beta+ data analysis system increased the sensitivity of the ICS up to levels comparable to the sensitivity of the ELISPOT assay., Conclusion: The IFN-gamma+ MIP-1beta+ data evaluation system provides a clear advantage for the detection of low magnitude HIV-1-specific responses. These results are important to guide the choice for suitable highly sensitive immune assays and to build reagent panels able to accurately characterize the phenotype and function of responding T-cells. More importantly, the ICS assay can be used as primary assay to evaluate HIV-1-specific responses without losing sensitivity in comparison to the ELISPOT assay.
- Published
- 2008
- Full Text
- View/download PDF
40. Therapeutic vaccination reduces HIV sequence variability.
- Author
-
Hoffmann D, Seebach J, Cosma A, Goebel FD, Strimmer K, Schätzl HM, and Erfle V
- Subjects
- Acquired Immunodeficiency Syndrome genetics, Acquired Immunodeficiency Syndrome immunology, Acquired Immunodeficiency Syndrome metabolism, Acquired Immunodeficiency Syndrome therapy, Base Sequence, Gene Products, nef genetics, Gene Products, nef metabolism, Genetic Variation genetics, Humans, Phylogeny, Sequence Analysis, DNA, T-Lymphocytes immunology, AIDS Vaccines immunology, AIDS Vaccines therapeutic use
- Abstract
With HIV persisting lifelong in infected persons, therapeutic vaccination is a novel alternative concept to control virus replication. Even though CD8 and CD4 cell responses to such immunizations have been demonstrated, their effects on virus replication are still unclear. In view of this fact, we studied the impact of a therapeutic vaccination with HIV nef delivered by a recombinant modified vaccinia Ankara vector on viral diversity. We investigated HIV sequences derived from chronically infected persons before and after therapeutic vaccination. Before immunization the mean +/- se pairwise variability of patient-derived Nef protein sequences was 0.1527 +/- 0.0041. After vaccination the respective value was 0.1249 +/- 0.0042, resulting in a significant (P<0.0001) difference between the two time points. The genes vif and 5'gag tested in parallel and nef sequences in control persons yielded a constant amino acid sequence variation. The data presented suggest that Nef immunization induced a selective pressure, limiting HIV sequence variability. To our knowledge this is the first report directly linking therapeutic HIV vaccination to decreasing diversity in patient-derived virus isolates.
- Published
- 2008
- Full Text
- View/download PDF
41. Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy.
- Author
-
Bickel M, Zangos S, Lutz T, Eisen J, Knecht G, Goebel FD, Crespi CM, Jacobi V, Staszewski S, and Klauke S
- Subjects
- Adolescent, Adult, Body Fat Distribution, Female, HIV-Associated Lipodystrophy Syndrome chemically induced, Human Growth Hormone administration & dosage, Humans, Male, Middle Aged, Pilot Projects, Prospective Studies, Antiretroviral Therapy, Highly Active adverse effects, HIV Infections complications, HIV Infections drug therapy, HIV-1 pathogenicity, HIV-Associated Lipodystrophy Syndrome drug therapy, Human Growth Hormone pharmacology, Intra-Abdominal Fat drug effects
- Abstract
Several studies have shown reduction of visceral adipose tissue (VAT) using recombinant human growth hormone (r-hGH) in HIV-1+ patients, but whether these effects are maintained after the end of treatment is unknown. In a prospective, randomized study we previously studied the effects of r-hGH 4 mg daily vs 3 times/week over 12 weeks, followed by a 2 mg daily maintenance dose for an additional 12 weeks. T1 weighted MRI flash sequences were performed of the face, abdomen and at mid-thigh level (MTF) at baseline, week 12, week 24 and at follow-up. Of 20 subjects who completed the 24-week study, follow-up is available for 16 patients (15 male, mean age 44.8 y, mean duration of HIV infection 13.5 y). After a median time of follow-up of 9 months, VAT remained overall 18% below baseline level (p =0.005). MTF was significantly reduced by 12% compared to its baseline level (p =0.03). Fasting glucose levels significantly improved by 21% compared to baseline (p =0.006). These results suggest that the achieved reduction of VAT using r-hGH in lipodystrophic HIV+ patients is in part maintained after a median follow-up of 9 months.
- Published
- 2008
- Full Text
- View/download PDF
42. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.
- Author
-
Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, Williams I, Drummond F, Duprez D, Belloso WH, Goebel FD, Grund B, Hatzakis A, Vera J, and Lundgren JD
- Subjects
- Adult, Anti-HIV Agents therapeutic use, Cardiovascular Diseases complications, Drug Administration Schedule, Drug Therapy, Combination, Female, HIV Infections virology, HIV-1 physiology, Humans, Male, Middle Aged, Reverse Transcriptase Inhibitors therapeutic use, Risk Factors, Treatment Outcome, Viral Load, Anti-HIV Agents administration & dosage, Cardiovascular Diseases epidemiology, HIV Infections complications, HIV Infections drug therapy, HIV-1 drug effects, Reverse Transcriptase Inhibitors administration & dosage
- Abstract
Background: The SMART trial found a raised risk of cardiovascular disease (CVD) events in patients undergoing CD4+ T cell-count guided intermittent antiretroviral therapy (ART) compared with patients on continuous ART. Exploratory analyses were performed to better understand the reasons for this observation., Methods: A total of 5,472 patients with CD4+ T-cell counts >350 cells/mm3 were recruited and randomized to either continuous ART (the viral suppression arm; VS) or CD4+ T-cell count-guided use of ART (the drug conservation arm; DC)., Results: Major CVD events developed in 79 patients. The hazard ratio (HR) for risk of CVD events for DC versus VS was 1.57 (95% confidence interval 1.00-2.46; P=0.05). There was no evidence that being off ART or a higher current HIV viral load were associated with increased CVD risk. Total cholesterol and low-density lipoprotein cholesterol were reduced as a result of ART interruption in DC patients but so was high-density lipoprotein (HDL) cholesterol, leading to a net unfavourable change in the total/HDL cholesterol ratio., Conclusions: Reasons for the higher risk of CVD for DC compared with VS patients remain unclear. There was no clear evidence to suggest that ART interruption per se or a higher HIV viral load were associated with an increased CVD risk in the DC group. Lipid changes were less favourable among DC compared with VS patients, which could offer a partial explanation.
- Published
- 2008
- Full Text
- View/download PDF
43. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.
- Author
-
Cosma A, Nagaraj R, Staib C, Diemer C, Wopfner F, Schätzl H, Busch DH, Sutter G, Goebel FD, and Erfle V
- Subjects
- AIDS Vaccines immunology, Adult, Antibodies, Viral blood, Antibody Formation immunology, Contraindications, HIV Infections drug therapy, Humans, Immunoglobulin G blood, Immunoglobulin G immunology, Retrospective Studies, Antibodies, Viral immunology, Antiretroviral Therapy, Highly Active, HIV Infections immunology, HIV-1 immunology, Smallpox Vaccine immunology, Vaccinia virus immunology
- Abstract
The fear of malevolent use of variola virus by terrorists has led to the implementation of a health care worker vaccination program and to the consideration of vaccination for the general public. However, due to concerns about side effects of the classical smallpox vaccine, especially for immunocompromised individuals, a safer vaccine is urgently needed. We characterized the immunogenicity of modified vaccinia virus Ankara (MVA), one of the more promising alternative smallpox vaccines, in a cohort of 10 chronically HIV-1-infected individuals undergoing highly active antiretroviral therapy (HAART). Nine subjects received smallpox vaccination as children while one subject was never vaccinated against smallpox. All the subjects had CD4 counts >400 cells/mm(3) and 8 out of 10 had undetectable viral loads. MVA was able to elicit humoral and cellular immune responses in the majority of individuals. Vaccinia-specific antibodies were mainly of the IgG class while T cells specific to vaccinia were predominantly CD8(+). The immune responses were maintained over 1 year. Similar vaccinia specific humoral immune responses were observed when our cohort of HIV-1-infected individuals was compared to smallpox-vaccinated healthy subjects. The observed immune responses suggest that the highly attenuated MVA could be used as a substitute vaccine against smallpox in chronically HIV-1-infected individuals undergoing HAART.
- Published
- 2007
- Full Text
- View/download PDF
44. Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.
- Author
-
Claas GJ, Jülg B, Goebel FD, and Bogner J
- Subjects
- Adenine adverse effects, Adenine therapeutic use, Adult, Aged, Anti-HIV Agents adverse effects, Anti-HIV Agents therapeutic use, Body Weight, CD4 Lymphocyte Count, Cholesterol blood, Cholesterol, HDL blood, Cholesterol, LDL blood, Creatinine blood, Didanosine adverse effects, Female, Glomerular Filtration Rate, Glycated Hemoglobin, HIV Infections blood, HIV Infections metabolism, Hemoglobins analysis, Humans, Lactic Acid blood, Male, Middle Aged, Organophosphonates adverse effects, Phosphates blood, Stavudine adverse effects, Tenofovir, Treatment Outcome, Triglycerides blood, Uric Acid blood, Viral Load, Adenine analogs & derivatives, Didanosine therapeutic use, HIV Infections drug therapy, Organophosphonates therapeutic use, Skinfold Thickness, Stavudine therapeutic use
- Abstract
Background: Nucleoside analogues such as Didanosine and Stavudine are known to cause metabolic and body habitus changes during antiretroviral therapy. The most frequently observed are lactic acidosis, hypercholesterinaemia, hypertriglyceridaemia and lipodystrophy., Methods: Over one year we monitored a cohort of 43 patients who switched from either Stavudine, Didanosine or the combination of both to Tenofovir. A group of 11 patients was kept on their original regimen and acted as control group. Blood samples were taken every 3 months from baseline, anthropometric measurements were performed at baseline, after 6 and 12 months., Results: During observation the levels of lactic acid and cholesterol decreased significantly in the switch group while virologic and immunologic efficacy remained stable. Serum creatinine levels rose significantly in patients switched to Tenofovir, but remained within physiological limits. The mean skin fold thickness increased significantly by 1.8 mm in the switch group after 6 months (p < or =0.001 - p = 0.032)., Conclusion: These results implicate an improvement of lipid profiles, serum lactate and lipodystrophy in HIV-positive patients after switch to Tenofovir. As a moderate increase in serum creatinine levels was observed, the renal function of patients on a Tenofovir-based regimen should be monitored closely.
- Published
- 2007
45. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.
- Author
-
Sternfeld T, Schmid M, Tischleder A, Mudra S, Schlamp A, Kost BP, Gruber R, Youle M, Bogner JR, and Goebel FD
- Subjects
- Acidosis, Lactic blood, Acidosis, Lactic chemically induced, Acidosis, Lactic immunology, Acidosis, Lactic virology, Adult, Anti-Retroviral Agents adverse effects, Antiretroviral Therapy, Highly Active adverse effects, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes virology, Cross-Sectional Studies, Fatty Liver blood, Fatty Liver chemically induced, Fatty Liver immunology, Fatty Liver virology, Female, HIV Infections blood, HIV Infections immunology, HIV Infections virology, HIV-Associated Lipodystrophy Syndrome blood, HIV-Associated Lipodystrophy Syndrome chemically induced, HIV-Associated Lipodystrophy Syndrome immunology, HIV-Associated Lipodystrophy Syndrome virology, Humans, Leukocytes, Mononuclear virology, Male, Middle Aged, Mitochondria virology, Mitochondrial Diseases blood, Mitochondrial Diseases immunology, Mitochondrial Diseases virology, Prospective Studies, Reproducibility of Results, Time Factors, Treatment Outcome, Anti-Retroviral Agents therapeutic use, CD4-Positive T-Lymphocytes drug effects, HIV Infections drug therapy, Leukocytes, Mononuclear drug effects, Membrane Potential, Mitochondrial drug effects, Mitochondria drug effects, Mitochondrial Diseases chemically induced
- Abstract
Objectives: Clinical disorders occurring in HIV-infected patients on antiretroviral therapy (ART) have been linked to mitochondrial dysfunction, for example, lactic acidosis and lipodystrophy. Mitochondrial membrane potential (delta psi m) is the most direct measure of the state of energization of the mitochondria. We analysed delta psi m, of peripheral blood mononuclear cells (PBMCs) in HIV-negative, healthy subjects (n=8), HIV-infected, treatment-naive patients (n=30), and HIV-infected patients on ART (n=58). The influence of ART was analysed in six patients who started their first regimen., Methods: The delta psi m of PBMC was measured by flow cytometry using the dye JC-1., Results: The delta psi m was significantly lower in HIV-infected patients than in HIV-negative controls. This difference was detected in both treated (P = 0.0001) and untreated patients (P = 0.001). The delta psi m of PBMCs was highly correlated with CD4+ T-cell count in therapy-naive patients (P = 0.002, r = 0.546) and in treated patients (P = 0.028, r = 0.288). The delta psi m increased significantly in therapy-naive patients after starting ART (P = 0.001). Patients with lipoatrophy had significantly lower delta psi m than patients without lipodystrophy or with lipohypertrophy (P = 0.023)., Conclusions: In HIV-infected persons delta psi m is significantly reduced. Patients with lipoatrophy have significantly reduced delta psi m. This is the first study showing that the delta psi m of PBMCs is highly correlated with CD4+ T-cell count in HIV infection.
- Published
- 2007
46. Clinical news from the XVI International AIDS Conference: The attempt of a summing up.
- Author
-
Jülg B and Goebel FD
- Subjects
- Antiretroviral Therapy, Highly Active, Drug Therapy, Combination, Humans, Acquired Immunodeficiency Syndrome drug therapy, Anti-HIV Agents therapeutic use
- Abstract
Topics highlighted at the XVI International AIDS Conference in Toronto included HIV/AIDS vaccine research, entry inhibitors, integrase inhibitors, new NNRTIs and PIs, single-agent therapies, pre-exposure prophylaxis and microbicides. Beside the large scientific part, policy and funding were of great concern. Within this article we are trying to focus on topics with direct clinical relevance. This includes new epidemiological and resistance data, results from current studies investigating established and novel antiretroviral drugs and drug classes as well as new findings in therapy management and strategies.
- Published
- 2006
- Full Text
- View/download PDF
47. Treatment interruption in HIV therapy: a SMART strategy?
- Author
-
Jülg B and Goebel FD
- Subjects
- Antiretroviral Therapy, Highly Active adverse effects, Antiretroviral Therapy, Highly Active standards, Drug Administration Schedule, Drug Resistance, Viral, HIV Infections immunology, HIV Infections virology, Humans, Treatment Outcome, Anti-Retroviral Agents administration & dosage, Anti-Retroviral Agents adverse effects, Anti-Retroviral Agents therapeutic use, Antiretroviral Therapy, Highly Active methods, HIV Infections drug therapy
- Abstract
Continuous HAART is standard of care for HIV-infected patients but lifelong adherence and tolerance are important concerns. Use of ART is associated with potential risks, e. g., adverse events, metabolic and cardiovascular complications, and HIV resistance. Stopping HIV therapy may reduce costs and side effects, but carries the risk of increased immune suppression and of emergence of resistance. Treatment interruption is a strategy of much interest, but its safety and efficacy have not been established. The clinical and biological characteristics that influence the outcome of structured treatment interruptions have not been fully clarified. In the following we will present the results of recent studies aimed to compare the long-term consequences of two antiretroviral-management strategies: continuous therapy versus scheduled treatment interruption.
- Published
- 2006
- Full Text
- View/download PDF
48. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy.
- Author
-
Röling J, Schmid H, Fischereder M, Draenert R, and Goebel FD
- Subjects
- AIDS-Associated Nephropathy epidemiology, Acute Kidney Injury etiology, Humans, Kidney Failure, Chronic etiology, AIDS-Associated Nephropathy etiology, Antiretroviral Therapy, Highly Active adverse effects, HIV Infections drug therapy
- Abstract
Renal disease is becoming an increasingly prevalent entity in human immunodeficiency virus (HIV)-infected patients; it occurs in a variety of clinical settings and is associated with histopathological changes. HIV-related renal impairment can present as acute or chronic kidney disease; it can be caused directly or indirectly by HIV and/or by drug-related effects that are directly nephrotoxic or lead to changes in renal function by inducing metabolic vaculopathy and renal damage. Acute renal failure is frequently caused by the toxic effects of antiretroviral therapy or nephrotoxic antimicrobial substances used in the treatment of opportunistic infections. Chronic renal disease can be caused by multiple pathophysiological mechanisms, leading to HIV-associated nephropathy, a form of collapsing focal glomerulosclerosis, thrombotic microangiopathy, and various forms of immune complex glomerulonephritis. The increase in life expectancy and alteration of lipid metabolism due to receipt of highly active antiretroviral therapy are expected to result in an increased prevalence of diabetes and hypertension and, thus, to secondary diabetic and hypertensive renal damage. Antiretroviral agents, such as indinavir and tenofovir, have been associated with nephrotoxic drug effects that have been shown to be reversible in most cases. In this article, we review the current knowledge about acute and chronic HIV-associated renal disease, metabolic alterations and related nephropathies, and toxic drug effects of combination antiretroviral pharmacotherapy.
- Published
- 2006
- Full Text
- View/download PDF
49. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
- Author
-
Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, and Lundgren JD
- Subjects
- Adenine analogs & derivatives, Adenine therapeutic use, Adult, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Female, HIV Infections virology, Humans, Lamivudine therapeutic use, Male, Middle Aged, Organophosphonates therapeutic use, Prospective Studies, Reverse Transcriptase Inhibitors therapeutic use, Tenofovir, Viral Load, Viremia drug therapy, Viremia immunology, Viremia virology, Zidovudine therapeutic use, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV Infections immunology, HIV-1
- Abstract
Background: It is unknown if the CD4 cell count response differs according to antiretroviral drugs used in combination antiretroviral therapy (cART) in patients with maximal virological suppression [viral load (VL) < 50 copies/ml]., Objectives: To compare the change in CD4 cell count over consecutive measurements with VL < 50 copies/ml at both time-points according to nucleoside backbones and other antiretrovirals used., Methods: Generalized linear models, accounting for multiple measurements within patients, were used to compare CD4 cell count changes after adjustment for antiretrovirals, time from starting cART, age, CD4 at first VL < 50 copies/ml, prior antiretroviral treatment, and change in CD4 cell count since starting cART., Results: We studied 28418 instances of VL < 50 copies/ml in 4041 patients. The mean annual change in CD4 cell count was +45.5/microl [95% confidence interval (CI) +39.4 to +51.6/microl). Comparing two drug nucleoside backbones, there was a lower annual change in CD4 cell count for zidovudine/lamivudine (n = 13038; -15.4/microl; P = 0.012) and for those on tenofovir (n = 1809; -27.3/microl; P = 0.029) compared to lamivudine/stavudine (n = 7339). Compared to the boosted-protease inhibitor regimen (n = 5915), use of an abacavir-based triple-nucleoside regimen was associated with a lower annual change in CD4 cell count (n = 2504 pairs; -26.1/microl; P = 0.011)., Conclusions: A nucleoside backbone of zidovudine/lamivudine or any tenofovir-based backbone was associated with significantly poorer increases in CD4 cell count compared to a nucleoside backbone of stavudine/lamivudine, as was an abacavir-based triple nucleoside regimen compared to a boosted protease inhibitor regimen. Long-term studies are needed to determine whether the differences in immunological response seen here translate into differences in the risk of clinical disease.
- Published
- 2006
- Full Text
- View/download PDF
50. Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.
- Author
-
Horster S and Goebel FD
- Subjects
- Benzoates adverse effects, Benzoates therapeutic use, Clinical Trials as Topic, Clinical Trials, Phase II as Topic, Cyclohexanes adverse effects, Cyclohexanes therapeutic use, Diketopiperazines, HIV-1 drug effects, Humans, Maraviroc, Piperazines adverse effects, Piperazines therapeutic use, Pyrimidines adverse effects, Pyrimidines therapeutic use, Spiro Compounds adverse effects, Spiro Compounds therapeutic use, Treatment Outcome, Triazoles adverse effects, Triazoles therapeutic use, CCR5 Receptor Antagonists, HIV Fusion Inhibitors adverse effects, HIV Fusion Inhibitors therapeutic use, HIV Infections drug therapy
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.